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ABSTRACT
NANCY BARCHUS BLOCK.

The Role of the Insulin Receptor Tyrosine Kinase

in Two Models of Insulin Resistance.

(Under the direction of MARIA

G. BUSE.)

Activation of the insulin receptor tyrosine kinase in vitro and in
vivo was studied in two rat models of insulin resistance:
cortiso1emia and streptozotocin-induced diabetes.

hyper-

In control rats,

intravenous insulin administration resulted in dose-dependent in vivo
activation of the skeletal muscle insulin receptor kinase.

Chronic

cortisone treatment did not affect the kinase activity of receptors
solubilized from muscle after activation with insulin in vivo or in
vitro.

In contrast, diabetes depressed skeletal muscle insulin

receptor kinase activation in vivo by -50%.

Diabetes impaired the in

vitro insulin stimulation of receptor kinase activity from skeletal
muscle and liver towards the substrate histone H2b, but not towards the
synthetic substrate poly glu-tyr (4:1).

To understand the mechanisms

underlying the substrate selective effects of diabetes, kinetics of
insulin receptor tyrosine kinase activity solubilized from control and
diabetic liver were examined.

Both substrates, histone H2b and poly

glu-tyr (4:1), inhibited insulin-stimulated autophosphorylation and
exogenous kinase activity when substrates were added prior to
activation of receptors with ATP.

Inhibition of insulin-stimulated

exogenous kinase activity by H2b was more marked with diabetic-derived
insulin receptors, resulting in a -70% lower maximal kinase activity
towards this substrate compared to receptors isolated from control

rats.

When receptors were allowed to autophosphorylate prior to

addition of H2b, substrate inhibition of kinase activity was minimal or
absent and the difference in maximal kinase activity between control·
and diabetic- derived receptors was reduced to -25%.

Kinetics of

insulin receptor kinase activity towards poly glu-tyr (4:1) were
unaltered by diabetes.

Effects of substrate-inhibition and diabetes on

insulin receptor kinase activity showed tissue-specific differences.
Liver-derived H2b kinase activity was inhibited to a greater extent by
H2b than that from muscle, and the effects of diabetes were greater in
liver than muscle.

The intrinsic (uninhibited) muscle insulin receptor

tyrosine kinase was unimpaired by diabetes.

Conclusions:

The insulin

resistance associated with hypercortiso1emia occurs distal to the
receptor kinase.

In vivo activation of the skeletal muscle insulin

receptor tyrosine kinase is impaired by diabetes.

Diabetes associated

impairment of the insulin receptor kinase activated in vitro reflects
mainly enhanced susceptibility of the receptor to inhibition by some
substrates, e.g., H2b.

This defect, which may result in impaired

signalling appears selective for substrates.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
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I. INTRODUCTION
Insulin is an anabolic peptide hormone with multiple effects on
its target cells.

These effects include:

1) activation of the

transport of molecules such as glucose, amino acids and ions across
the plasma membrane (284); 2) acute activation or inhibition of
intracellular enzymes involved in intermediary metabolism (62,256);
3) regulation of gene expression (84); 4) translocation of membrane
proteins such as the glucose transporter (52,249,258). and the type II
insulin·1ike growth factor receptor (62,162); and 5) stimulation of
cell growth (257).

Activation of enzymes and transport occurs over

relatively short time periods (seconds to minutes) while processes
leading to cell growth and proliferation occur over much longer periods
of time (hours).

Pleotypic effects of insulin are observed in many

cell types, however some effects are tissue-specific.

Much of our

understanding of insulin's actions is based upon its effects in the
three major physiologic target tissues in mammals:

muscle, liver and

adipose tissue.
Despite intense efforts to elucidate the mechanisms involved in
insulin action, the exact sequence of events which lead to effects
following insulin binding remain undefined.

Insulin's actions are

initiated upon binding to a specific receptor on the surface of its
target cells.

A vast amount of knowledge concerning the structure and

3

function of the insulin receptor has been obtained (reviewed in
53,86,129,225 187) but evidence concerning the regulation of insulin
J

receptor function and it's coupling to insulin's effects is still
incomplete.

Studies presented in this dissertation addressed the

regulation of insulin receptor structure and function in two animal
models of insulin resistance in two major target tissues.
II •

INSULIN RECEPTOR STRUCTURE

A. Biochemical Studies:
The insulin receptor is found in virtually all mammalian cell
types.

Because the number of insulin receptors (-10 2 - 10 5 per cell)

is relatively low compared to most

p~oteins

(62,114,129), much of the

initial information regarding the structure of the receptor was derived
from tissues such as human placenta and rat liver from which large
amounts of the protein could be purified, or from cultured cell lines
labelled with receptor precursors.

Biochemical studies in several

laboratories (81,103,105,116,117,118,135,170,171,207) revealed that the
insulin receptor is a heterotetramer transmembrane glycoprotein
consisting of 2 a subunits (M.W.

~135

kDa) and 2

a subunits

(M.W. -95

kDa) linked by disulfide bonds in a S-S-S-a-a-S-S-6 configuration
(depicted in figure 1).

The

a subunits contain the ligand binding

domain and reside totally extracellularly while the

a subunits

are

transmembrane peptides, containing a small extracellular domain, a
membrane spanning domain and a much larger intracellular domain.
Pulse chase studies with IM-9 lymphocytes (104) and 3T3-Ll cells
(223) showed that the receptor is synthesized as a single polypeptide
(180-190 kDa) which is cotrans1ationally glycosy1ated.

Following
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core-N-1inked glycosylation to a high mannose form in the endoplasmic
reticulum (210 kDa), the precursor is transferred to the Golgi where
the single chain is cleaved to form -125 kDa and -85 kDa subunits.
These subunits are then further processed in the Golgi by conversion to
a low mannose form, and addition of other monosaccharides including
glucosamine, fucose and sialic acid.

Both the mature a

and 8 subunits

are glycosylated, with a greater amount of galactose and
N-acetylglucosamine in the former and a higher sialic acid content in
the latter (105).

Inhibitors of glycosylation result in the intracel-

lular accumulation of aglycoreceptor protein and decreased cell surface
binding (224,226).

Removal of these inhibitors results in the

appearance of fully glycosylated forms of the previously accumulated
protein, indicating that glycosylation may be necessary for insertion
of the receptor into the plasma membrane (226).

The insulin receptor

is also post-translationally modified by palmitic and myristic
acylation.

This modification has been shown to be necessary for the

interaction of proteins with the plasma membrane (271).
B.

Molecular Biology:

The basic structure was confirmed after cloning and sequence
analysis of the human placental insulin receptor independently by
Ullrich et a1. (273) and Ebina et al. (69).

cDNA sequence analysis by

these two groups was essentially identical except that one group
reported a sequence of 1370 amino acids while the other group's
sequence was longer by 12 amino acids at the 3' end of the a subunit.
These differences were attributed to isolation of different mRNA
species used for cDNA synthesis.

Sequence analysis identified a leader
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peptide sequence at the amino terminus of the a subunit which is
cleaved after insertion of the proreceptor into the endoplasmic
reticulum membrane, and a domain of cationic amino acids which forms
the cleavage site yielding the a and B subunits.
the

The region encoding

B subunit revealed a sequence of hydrophobic amino acids encoding

the membrane spanning domain, in addition to a consensus sequence for
ATP binding and a region encoding phosphotransferase activity.
Sequencing also revealed multiple potential glycosylation sites and
regions of high cysteine content in the a subunit

t

whereas the

subunit contained lower quantities of both types of residues.

B

The

predicted M.W. from sequence analysis is 82 kD for the a subunit and 69

kD for the 8 subunit; the differences between predicted and observed
M.W. likely owing to glycosylation and anomalous migration on
SDS-PAGE.
The insulin receptor contains significant sequence homology to the
tyrosine kinase family of oncogenes and other growth factor receptor
tyrosine kinases, including the epidermal growth factor (EGF) , platelet
derived growth factor (PDGF), and the insulin·like growth factor 1
(IGF-l) receptors (69,273,296).

Highly homologous regions in these

receptors include the ligand binding (including cysteine-rich regions),
ATP binding and phosphotransferase domains.

Exceptional structural and

functional similarity exists between between the insulin receptor and
the insulin-like growth factor I receptor (115,118,255,274,296) and
between their respective ligands (222).

Both receptors share binding

of each other's ligands, albeit at very different ligand concentrations
(27,209 222).
t
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Southern blot analysis after treatment of DNA with restriction
enzymes indicated that there is only one insulin receptor gene in
humans (273) while northern blot analysis indicated multiple mRNA
species in humans (2 main species) and at least 2 in rats (69,273),
suggesting that insulin receptor mRNA is processed differently.

Using

the polymerase chain reaction, Seino et ale (245) showed that alternate

mRNA splicing leads to two mRNA isoforms in several human tissues
(liver, kidney, brain, spleen and adipose) and in IM-9 lymphocytes and
Hep G2 cells.

In addition the abundance of the two types of

transcripts varies between different tissues and cell lines.
Differences in the migration of insulin receptors from different
tissue types on SDS-PAGE have been observed in rats (28,107) and humans
(35) and were attributed in part to altered sialylation of insulin
receptor S subunits (28).

Alternative mRNA splicing is a common

mechanism for the generation of protein isotypes; whether differences
in the structures detected between tissues after SDS-PAGE are due to
alternative splicing is unknown.

III.

INSULIN BINDING
A.

Kinetics:

Equilibrium insulin binding to solubilized receptors, isolated
plasma membranes and intact cells reveals complex interactions.
Scatchard plots of insulin binding are generally curvilinear indicative
of either at least two distinct affinity binding sites or
negative cooperativity between two or more similar sites (53).
Evidence for negative cooperativity was first shown by DeMeyts et ala
(60,61) where excess unlabelled insulin promoted dissociation of the

7

labelled bound hormone from cultured lymphocytes and most recently in
highly purified receptor preparations (280).

Using a similar

experimental design, however, Pollet et al. (210) found enhanced
dissociation of bound hormone from cultured lymphocytes under
conditions in which binding site occupancy decreases and argued against
negative cooperativity as an explanation for nonlinear binding
kinetics.

In addition, evidence for positive cooperativity has been

demonstrated at very low insulin concentrations (64,65).

The proposed

symmetrical a2 8 2 structure lead early investigators to believe that two
kinetically distinct binding sites exist per receptor molecule with the
potential for binding site cooperativity between the two sites.
However, studies in several laboratories indicated that only 1 mol of
insulin binds per mol of receptor (21,201.259).
B. Structural Components of the Receptor Involved in Insulin
Binding:
Additional studies provided insight into the structural basis for
complex insulin binding kinetics.

Mild reduction of solubilized

insulin receptors with dithiothreiotol (DTT) selectively reduces
sulfhydryl bonds between a subunits, generating two a-S-S-S
heterodimers (20,21,185,259,260).

After separation of experimentally

generated placental insulin receptor tetramers and dimers by gel
filtration, Koch et a1. (147) observed that optimal insulin binding to
the two types of receptor species occurs at different pH and ionic
strengths.

Scatchard Plots indicated a single low affinity binding

site in the dimer form, and a distinct high and low affinity binding
site in the tetramer (259).

At saturation, one molecule of insulin was

8

bound per dimer or tetramer.

The authors suggested that half site

binding reactivity in dimers indicates that insulin binding to tetramers displays either absolute negative cooperativity or that the
subunits are associated assymetrically.

Curvilinear Scatchard plots of

insulin binding to the isolated tetramer fractions suggested that
multiple native forms (possibly higher association states of individual
subunits) of the receptor exist.

Alternatively, the association of 2

dimer halves may form a complete high affinity binding site in the
tetramer and the low binding affinity component observed in tetramer
fractions may be due to contamination by a small number of dimers.
The 02 82 form of the insulin
detected in vivo (53).

re~eptor

is the predominant species

a-S-S-8 Dimers have been isolated from liver

plasma membranes without the addition of DTT (147,169).

Whether these

dimers were artifacts of the preparation or exist natively in vivo is
unknown.

Data presented in chapter three of this dissertation suggest

the former.
Sulfhydryl interactions may play a role in insulin action and
insulin receptor activation (discussed in section VII).

An early study

by Maturao et al suggested that disulfide exchange occurs in the
insulin receptor upon insulin binding because changes in the
hydrodynamic state of the receptor were observed following insulin
binding and were mimicked by DTT (172).

Yip and colleagues (297)

localized the insulin binding site to the cysteine-rich region of the
subunit after proteoltyic digestion of the a subunit labelled with a
photoreactive insulin analog.

In this study, transfection of insulin

receptors mutated by deletion of this site into chinese hamster ovary

9

(CHO) cells failed to increase insulin binding to these cells whereas
transfection of the same amount of normal receptors increased binding
"10 fold.
Glycosylation of cell surface proteins has long been recognized as
an important component of interactions with extracellular molecules.
The role that glycosylation of the insulin receptor plays in insulin
binding or action is not well defined.

Removal of terminal sialic acid

residues from the insulin receptor with neuraminidase was shown to have
either no effect (134) or resulted in increased insulin binding (82).
Removal of adipocyte cell surface sialic acid residues by levels of
neuraminidase which had no effect on insulin receptor sialic acid
residues markedly reduced the ability of insulin to stimulate
lipogenesis and inhibited receptor recycling indicating a role of
non-receptor glycoconjugates in insulin action (101).
IV •

INTERNALIZATION OF INSULIN AND ITS RECEPTOR

A.

Characterization:

Several morphologic and biochemical studies have shown that the
insulin-receptor complex is internalized following insulin binding
(8,11,74,136,154,168,218,240).

This process, termed ttreceptor-mediated

endocytosis" is the means by which many types of ligands, including
LDL, transferrin, asialoglycoproteins, mannose glycoconjugates,
lysosomal enzymes and a2-macrog1obulin, enter cells and reach their
intracellular destination (74,111).

Morphologic studies indicated that

insulin initially binds diffusely on the cell surface, but then
aggregates into patches before it is internalized (240).

Internali-

zation of the insulin receptor can be mimicked by binding of some
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antibodies directed against the a subunit of the insulin receptor which
inhibit insulin binding (127).

Aggregation of the receptor

(127,192,239), stimulation of glucose transport in rat adipocytes (127)
and activation of solubilized liver insulin receptor kinase activity
(106) (discussed in section V) was induced by the binding of bivalent
Fab fragments, but not monovalent fragments of these antibodies indicating that receptor aggregation is an important event in insulin
action.
Internalized insulin receptors have been shown to have at least
three fates (111):

Insulin receptor complexes can be 1) rapidly

recycled back to the cell surface (74,89), 2) sequestered in an
intracellular compartment (154), or 3) degraded by lysosomes (11,168).
Half life of the receptor is believed to be largely a result of the
rate of degradation (287).
hours.

In the absence of insulin it is -9-12

Upon short term exposure to insulin most receptors are cycled

back to the plasma membrane (74).

However, after long term exposure

to insulin, receptor degradation increases (136,146) resulting in a
decrease in the number of plasma membrane receptors.

This phenomenon,

termed ndown-regulation" is characteristic of many types of receptors
after chronic exposure to ligand (49,126) and may be responsible for
altered response to insulin in some cells under conditions associated
with hyperinsulinemia (76) (discussed in section X).

Conversely,

receptor number is increased or "up-regulated tt under conditions where
circulating insulin levels are low (30,123).
B.

Consequences of Internalization:

Some of insulin's effects may depend on internalization of the

11
hormone.

Inhibition of internalization or intracellular processing

with monensin, chloroquine or methylamine selectively blocked some of
insulin's effects in several cell types (66,86,213).

While specific

binding of insulin to intracellular organelles; including the Go1gi
apparatus, endoplasmic reticulum and nucleus have been demonstrated
(87), the consequences of these interactions are uncertain.

Maller et

al. (166) and Miller et ale (180) demonstrated increases in ribosomal
S6 phosphorylation, RNA synthesis and protein synthesis following
microinjection of insulin into Xenopus oocytes.

In addition Miller

(179) showed that RNA and protein synthesis could be stimulated by
applying insulin to isolated nuclei and isolated cytoplasm,
respectively, from Xenopus oocytes.

These last three studies indicate

that at least some of insulin's effects can be e1icted after bypassing
the plasma membrane.

Whether insulin exerts these effects in vivo by

this mechanism is questionable, since effects seen in the cell free
systems were additive
V•

to

insulin applied externally to cells.

THE INSULIN RECEPTOR TYROSINE KINASE

A.

Identification and Characterization:

Phosphorylation of the S subunit of the insulin receptor in
response to insulin was demonstrated initital1y in cultured human
lymphocytes by Kasuga et a1. (137).

This event was subsequently

verified in a number of cell types and in cell free systems.

In

intact cells the phosphorylation occurred on both serine and tyrosine
residues (95,137,202,292), while in cell free systems, phosphorylation
was primarly on tyrosines (7,138 t 303).

Additionally, insulin

stimulated the tyrosine phosphorylation of proteins added to detergent
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extracts of cells or purified receptor preparations (205,304).

While

it was originally postulated that phosphorylation resulted from a
distinct protein kinase which copurified with the insulin receptor,
further studies using insulin receptors purified to near homogeneity
indicated that the tyrosine kinase activity was an intrinsic property
of the insulin receptor (109,303,306).

Serine phosphorylation

presumably occurs by the action of distinct intracellular and/or
membrane bound kinases which are activated in response to insulin

(54,202).
The kinase activity of the insulin receptor has been characterized
by numerous independent groups.

The phosphotransferase activity was

localized to the S subunit after selective trypsin digestion of the
subunit was shown to abolish kinase activity without affecting insulin
binding (229) and by demonstration of an ATP binding site in this
subunit (228,246).

Rosen et al. (227) originally showed that tyrosine

kinase activity towards exogenously added substrates in cell free
systems was enhanced when the insulin receptor was allowed to
phosphorylate prior to addition of substrates, indicating that
autophosphorylation of the insulin receptor activated its intrinsic
kinase activity.

It was subseqently shown by several groups that

autophosphorylation occurs on several sites of the S subunit (at least
11), but that activation of exogenous kinase activity correlated only
with the phosphorylation of some tyrosine residues within a specific
tryptic domain (109,269,303).

White et a1. (286) further showed that

phosphorylation of different tryptic domains occurred with different
time courses.

Utilizing antiphosphotyrosine antibodies to trap the
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receptor in a given phosphorylation state followed by conditions which
inhibited further autophosphorylation, this group showed that
autophosphorylation of the 8 subunit proceeds via a cascade in
receptors isolated from Fao hepatoma cells (290).

Progression of the

cascade to two sites (tyr 1146 and either 1150 or 1151) in the critical
domain (designated the tyr 1150 domain) resulted in partial activation
and subsequent phosphorylation of a third site in this domain resulted
in full activation of exogenous kinase activity in vitro.

The cascade

was completed by phosphorylation of two other sites (tyr 1316 and 1322)
near the COOH terminus, which had no effect on activation.
The extent of insulin receptor

~utophosphorylation

and exogenous

kinase activity parallels receptor occupancy by insulin (7); with
solubilized receptors, half maximal binding and half maximal kinase
activity occur with -2 X 10- 9 M insulin.

After the insulin receptor is

activated by autophosphorylation, the presence of insulin is no longer
required for continued activity (227,306).

Insulin stimulates insulin

receptor tyrosine kinase activity by increasing the Vmax for ATP, while
the Km for ATP is unaltered (156,187).

The kinase activity is

dependent on either Mn 2+ or Mg2+ which decrease the Km for ATP
(156,187), thus the concentrations of these cations required for
maximal activity are highly dependent on ATP concentrations.

Under in

vitro conditions, where typically < 0.5 mM ATP is utilized, the
reaction utilizes Mn 2+ in preference to Mg2+.
Autophosphorylation may not be absolutely necessary for activation
of exogenous insulin receptor tyrosine kinase activity:

Following

incubation of highly purified placental insulin receptors with
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concentrations of substrates which completely inhibited
autophosphorylation, a two fold insulin stimulation of exogenous kinase
activity was still observed (186).

In addition, some types of insulin

receptor antibodies can stimulate exogenous kinase activity without
increasing insulin receptor autophosphorylation (12).
B.

Regulation:

Dephosphorylation of the receptor by experimental addition of
alkaline phosphatase results in inactivation of previously activated
receptors in vitro (97,303).

Using pulse-chase techniques in

permeabilized rat adipocytes, Mooney et ale (182) showed that
phosphorylated receptors are rapidly dephosphorylated (by 2 minutes).
Klein et a1. (144) and Backer et a1. (8) showed that internalized
phosphorylated adipocyte and Fao hepatoma cell receptors are
dephosphorylated more rapidly than those on the plasma membrane.
Inactivation in vivo presumably occurs by the action of intracellular
phosphatases since phosphatase activity is not detected in highly
purified receptor preparations (97).
Comparison of autophosphorylation in vivo with that in vitro by
several groups indicates that some tyrosines which are phosphorylated
in vitro seem not to be accessible to phosphorylation in vivo
(18,32,290,292).

In Fao hepatoma cells, phosphorylation of the third

critical site did not occur in vivo (292), however insulin binding to
intact rat adipocytes (143) and intact rat skeletal muscle (32)
resulted in essentially full receptor activation indicating that
regulation in vivo may vary with cell type.

Examination of phos-

phorylation over time in vivo by Pang et a1. (202) showed that the
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insulin receptor is phosphorylated initially on tyrosines in response
to insulin and subsequently on serine and threonine residues.
Phosphorylation on serine and threonine residues decreases the
exogenous tyrosine kinase activity of the receptor and is elicited in
vivo by administration of agents which increase cAMP or by phorbo1
esters (115,263,264).

Receptor preparations are also phosphorylated on

serine residues in vitro by protein kinase C resulting in decreased
tyrosine kinse activity (19).

Serine and threonine phosphorylation,

thereby serve as a mechanism to regulate insulin receptor tyrosine
kinase activity.
Effects of proteolysis on autophosphory1ation and exogenous kinase
activity are controversial.

Mild trypsinolysis of the 8 subunit of

receptors from Fao cells decreased autophosphorylation due to the loss
of tyr 1316 and 1322 residues; however this treatment did not affect
the activation of exogenous phosphotransferase activity towards a
synthetic peptide substrate corresponding to amino acid residues 1143
to 1152 (thr-12-lys) of the human insulin receptor (290).

Receptors

similarly degraded by a membrane splitting proteinase possessed
decreased autophosphorylation and normal maximal exogenous kinase
activity towards a synthetic peptide substrate (poly glu-tyr 4:1)t but
apparently decreased affinity for the substrate (244).

However, others

found that proteolytic degradation resulting in barely detectable
molecular weight changes, resulted in abolition of placental insulin
receptor autophosphorylation and exogenous kinase activity towards
histone H2b and

thr~12·lys

(140).

In contrast, mild proteolysis of the

asubunit apparently activates insulin receptor tyrosine kinase activity
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(161) (discussed in secion VII).

VI.

THE INSULIN RECEPTOR TYROSINE KINASE AND SIGNAL TRANSDUCTION
Several lines of evidence indicate that activation of the insulin

receptor tyrosine kinase is a necessary event for most of insulin's
biologic actions.
A.

Studies with Antibodies:

Antibodies against the 8 subunit which inhibit insulin receptor
autophosphorylation and exogenous tyrosine kinase activity inhibited
multiple insulin sensitive pathways (including short and long term
effects of insulin) when introduced intracel1ular1y by microinjection
into Xenopus oocytes (183) or by osmotic lysis of pinocytotic vessicles
that contained the antibodies in rat adipocytes, HepG2 and CHO cells
(184).

Antibodies against the S subunit which do not inhibit insulin

receptor tyrosine kinase activity had no effect.
An antibody against the

~

subunit which activated the insulin

receptor kinase, stimulated amino acid transport but not cell proliferation in hepatoma cells (211).
proposed mechanism of

r~ceptor

These results support an alternative

activation whereby insulin binding may

serve only to alter the conformation of the receptor, resulting in
non-covalent interaction of the receptor with plasma membrane proteins
similar to receptor systems which interact with G-proteins (129).

This

interaction may be essential for coupling to some, but not all of
insulin's effects.

While this is a p1ausable mechanism, results

obtained with antibodies must be interpreted cautiously because
insulin-mimetic actions of antibodies may proceed by mechanisms other
than which actually occur in response to insulin in vivo.(212).

17
B.

Mutation of the Insulin Receptor:

Selective mutation of the cloned insulin receptor gene proved to
be a powerful tool for elucidating the mechanisms involved in insulin
receptor activation and for establishing the role of the kinase in
coupling to post-receptor events.

Site-directed mutagenesis at either

the ATP binding site (40,68) or at a critical tyrosine (tyr 1150) (71)
resulted in kinase deficient receptors without altering insulin
binding, internalization or processing.

CHO cells expressing the

kinase deficient receptors after transfection with the mutated insulin
receptor gene were considerably less sensitive to insulin than cells
transfected with the normal insulin receptor gene; with regards to
glycogen synthesis, thymidine incorporation into DNA, hexose uptake,
ribosomal protein 56 kinase activation t endogenous tyrosine
phosphorylation of cellular proteins and serine and threonine
phosphorylation of the insulin receptor.
Expression of a similarly mutated (ATP binding site) human kinase
deficient receptor in rat 1 fibroblasts was shown to inhibit: a)
stimulation of hexose uptake, b) receptor internalization and c)
endogenous insulin receptor function in vivo at the level of substrate
phosphorylation even though autophosphorylation of the endogenous
receptor was not impaired (164).

This study indicated that exogenous

kinase activity in addition to autophosphorylation is necessary for
generating insulin's signal, at least with regards to glucose uptake.
Interestingly, the kinase deficient receptors did not inhibit
phosphorylation of substrates in vitro when mixed with normal
receptors; however, the different results could be due to potentially
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limiting substrate levels in vivo vs the use of saturating substrate
levels in vitro.
Not surprisingly, two studies indicated that other features of the
insulin receptor molecule are important for signal transduction:

1)

Mutation of the insulin receptor at tyrosine residue 960 did not affect
autophosphory1ation or exogenous substrate (thr-12-1ys) phosphorylation
by the receptor in vitro (288).

These results are consistent with

results of biochemical studies indicating that phosphorylation of this
site is not necessary for activation of exogenous kinase activity
(290).

2) Experimental truncation of the insulin receptor by mutation

of the carboxyl terminus of the gene.also did not affect
autophosphorylation or exogenous kinase activity towards a synthetic
polypeptide (poly glu·tyr 4:1) in vitro (163,175).

Neither of these

two mutated receptors were biologically active when expressed in CHO
cells or rat 1 fibroblasts and the first mutation resulted in markedly
decreased phosphorylation of an endogenous substrate (pp185).

Both of

these studies confirmed that autophosphory1ation is not sufficient for
transmission of insulin's signal and further supported a role of
exogenous protein kinase activity in signal transmission.

In addition,

results from these studies indicate that altered insulin receptor
structure induced by some mutations may alter recognition of endogenous
substrates but not synthetic peptide substrates.

Therefore, these

studies suggest that the synthetic peptide substrates utilized for in
vitro assays may not be good models for the in vivo substrates.
Results presented in chapter three of this dissertation indicate that
structural alterations in the insulin receptor induced by diabetes may

19
be expressed towards synthetic peptides differently than globular
proteins.
VII..

CONFORMATION OF THE INSULIN RECEPTOR AND SIGNAL TRANSDUCTION

Insulin induced conformational changes and association between
subunits are crucial events in signal transduction by the receptor.
Early evidence for a conformational change following insulin binding
was shown by altered response of the receptor to radiation inactivation (98) increased susceptibility of the a subunit to proteases
(161,208), altered receptor mobility in molecular sieving columns
(172), a shift to higher insulin binding affinity (64,65), potentiation
of reducing agents (293) and by changes in kinase activity.
A number of agents (trypsin, H202, DTT) which are insulinmimetic,
alter the structure of the insulin receptor and activate the insulin
receptor tyrosine kinase (113,121,151,248,261,285).

Several lines of

experimentation which include the use of these agents indicate that the
a subunit exerts inhibitory control of 8 subunit kinase

activ~ty

and

that insulin binding to the a subunit releases the S subunit from this
inhibitory control:

Trypsin digestion of the a subunit using either'

solubilized receptors or intact cells confered constitutive kinase
activity upon the

a subunit

(113,248).

Truncation of the a subunit by

deletion mutagenesis and expression in CHO cells resulted in a
constitutively elevated insulin-independent uptake of glucose (70).

In

liver membranes, insulin binding resulted in proteolytic degradation of
the a subunit by an endogenous protease without degradation of the
subunit (161), even though in vitro it is the 8 subunit which is
selectively sensitive to exogenously added proteases (140,229)

B
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suggesting that a proteolytic event may be involved in activation of
the kinase by insulin in vivo.

Mild reduction with DTT results in the

formation of two a-B dimers and increased insulin independent
kinase activity (260).

B subunit

Activation by this agent therefore also

involves a release of constraints by the a subunit structure.
Interaction between a-B dimers appears to be necessary for full
activation of the insulin receptor tyrosine kinase as insulin stimulated autophosphory1ation of a-S dimers is lower than native tetramers
(20,260).

However, the lower insulin-stimulated kinase activity may be

due to elevated basal levels.

Autophosphorylation promotes

reassociation of dimers to tetramers as demonstrated by sizing
chromatography of isolated dimers before and after exposure to ATP and
Mn 2+ (185).

Examination of the reassociated species by non-reducing

SDS-PAGE indicated that in the presence of insulin the reassociation is
covalent; in the absence of insulin it is not (185).
One of the obvious questions which arose soon after the discovery
of the phosphotransferase activity of the B subunit, was whether
autophosphorylation occurs through an intra- or inter- molecular
reaction.

Dilution was shown not to affect autophosphorylation of

solubilized receptors indicating an intramolecular reaction (246).

However. the existence of two 8 subunits per tetramer raised the
possibility of several mechanisms: the phosphorylation of each subunit
by itself, cross·phosphorylation of one 8 subunit by the other, or a
combination of both mechanisms.
the second mechanism:

1)

Results from two experiments suggested

Dimers immobilized on WGA failed to

autophosphorylate (20) and 2) dilution of receptor dimers decreased the
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rate of autophosphorylation in a dilution-dependent manner (260).
VIII.

ENDOGENOUS SUBSTRATES FOR THE INSULIN RECEPTOR KINASE
Several insulin sensitive enzymes are regulated by phosphory-

lation/dephosphorylation mechanisms.

These include glycogen synthase,

pyruvate dehydrogenase, cAMP phosphodiesterase, acetyl-CoA carboxylase
and ribosomal S6 kinase (62,225).

Most of these enzymes are activated

by dephosphorylation in response to insulin and until recently (214)
only serine and threonine phosphorylation was detected in the enzymes
which are activated by phosphorylation.

This lead to the hypothesis

that other serine and threonine kinases or phosphatases were
phosphorylated by the insulin receptor on tyrosine, which in turn
phosphorylated or dephosphorylated insulin sensitive enzymes.

Early

attempts to identify in vivo substrates for the receptor demonstrated
tyrosine phosphorylation of several proteins in different cells types,
although the identity or role that most of these proteins play in
mediating insulin's signal is unknown (1,14,16,97,112,206,232,167,
124,289).

Four of these phosphoproteins deserve mention as specific

properties which may re,late to signal transduction by insulin have been
identified:
1)

Colca et a1. (45) reported insulin stimulated tyrosine

phosphorylation of calmodulin in intact adipocytes.

Calmodulin, a

ubiquitous calcium binding protein, regulates a number of calcium-sensitive enzymes (39).

Insulin has been shown to increase Ca 2+ and

calmodulin binding to adipocyte plasma membranes and to inhibit
calmodulin-dependent plasma membrane Ca 2+ and Mg2+ ATPase (45).
insulin receptor specifically binds calcium and calmodulin (45);

The
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however, phosphorylation of calmodulin in vitro by the insulin receptor
has an absolute requirement for cationic peptide cofactors including
polylysine

t

histone H2b and the carboxyl terminus of C-Ha-ras

(90,23l 295).
t

2)

O'Brien et a1. (190) reported phosphorylation of a 60 kDa GDP

binding protein on tyrosyl residues following insulin stimulation of
mouse NIH-3T3 cells and suggested that this protein was an
insulin-sensitive G protein.

Krupinski et a1. (153) had previously

demonstrated that insulin receptors can phosphorylate the Go or Gi
proteins of the adenylate cyclase system in detergent solubilized
systems and after incorporation of the receptor and the G proteins into
phospholipid vesicles.

In addition purified placental insulin

receptors phosphorylated purified N-ras p21 protein (a member of the G
protein family (37»

in an insulin dependent manner in vitro (150).

Furthermore, microinjection of antibodies directed against H-ras p2l
into Xenopus oocytes inhibited insulin, but not progesterone stimulated
maturation of these cells (150).

In a variety of cell types, insulin

stimulates the hydrolysis of an inositol-glycan mediator which
subsequently activates insulin senstive enzymes (73,235).

This effect

occurs following activation of an inositol-specific phospholipase C.
It has been suggested that this function may be mediated by
interaction of the insulin receptor with a G protein, similar to other
receptor systems which activate phospholipase C (43).
3)

Microtubule associated protein-2 (MAP-2) kinase is a

serine/threonine specific kinase which activates ribosomal S6 kinase
from Xenopus oocytes (216).

Tyrosine phosphorylation of MAP-2 kinase
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was detected after exposure of 3T3-Ll cells to insulin (217).
Increased S6 phosphorylation has been associated with increased protein
synthesis in Xenopus oocytes, swiss mouse 3T3 fibroblasts and rat
adipocytes (262).

In pancreatic acini, 56 kinase was activated in a

time and dose-dependent manner by insulin (262).
4)

Most recently, Pyne et a1. (214) demonstrated that insulin

stimulates tyrosine phosphorylation and activation of the 52 kDa
peripheral plasma-membrane cyclic AMP phosphodiesterase in intact
hepatocytes (214).

In addition, prior treatment of hepatocytes with

glucagon, a catabolic hormone which acts antagonistically to insulin,
prevents the phosphorylation and activation.

This finding is

especially significant, as this is the first protein whose function is
known to be regulated by insulin and the consequences of its function
on a cellular process known.
IX.

IN VITRO MEASUREMENT OF INSULIN RECEPTOR KINASE ACTIVITY

Studies involving assessment of insulin receptor kinase activity
in vitro rely on the use of exogenously added substrates.

While

purification procedures resulting in highly purified receptors are
essential for determination of activity intrinsic to the receptor,
procedures resulting in the highest degree of purity involve elution of
receptors from insulin or antibody affinity columns under relatively
harsh conditions.

Glycosyl residues in the receptor enables affinity

purification by immobilized lectins (103) involving elution at neutral
pH with competetive sugars

J

and results in insulin receptors with

greatly increased kinase activities compared to those eluted under
harsh conditions (186,221).

Therefore, assessment of kinase activity
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in vitro is often

p~rformed

on WGA purified receptors; a semi-purified

preparation which contains other glycoproteins including other
membrane-bound tyrosine kinases.
Several synthetically derived or other exogenously added
substrates are used to assess insulin receptor tyrosine kinase activity
in vitro.

The most commonly used substrates include histone H2b, a

synthetic copolymer of glutamic acid and tyrosine residues (poly glutyr 4:1), a synthetic peptide corresponding to the phosphorylation
sequence of the src oncogene product (src related peptide), angiotensin
II, and a synthetic peptide corresponding to the insulin receptor
subunit sequence between residues 1143 and 1152 (thr-12-lys).

Most of

these polypeptides serve as excellent substrates for several tyrosine
kinases, but often with different kinetics (23,142,238,247,254,276).
In addition, only the IGF-l receptor possesses binding cross-reactivity
with insulin but requires -100 fold higher levels of insulin than the
insulin receptor to achieve similar levels of receptor
(27,28,302).

occupa~cy

Therefore in vitro reactions stimulated by insulin are

relatively specific for the insulin receptor even though basal
activities may be contributed by copurified tyrosine kinases.

Recently

a purification scheme has been described in which receptors can be
eluted from insulin affinity columns under relatively mild conditions
and results in highly purified receptors possessing kinase activity
similar to that of WGA preparations (221).

The use of this method may

allow more sensitive means to asses insulin receptor kinase activity in
vitro in the future.
Many substrates for the insulin receptor tyrosine kinase inhibit
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insulin stimulated insulin receptor autophosphorylation and exogenous
kinase activity at levels above their Km, when substrates are added
before addition of, or simultaneously with ATP during insulin receptor
activation (23,148,156,233,248).

In general, if insulin receptors are

maximally activated by autophosphorylation before the addition of
substrates, no inhibition of autophosphorylation or insulin receptor
tyrosine kinse activity is observed.

Some synthetic polymers were

shown to inhibit exogenous kinase activity when added either prior to
or after autophosphorylation; however higher levels of substrate were
needed to inhibit kinase activity when added after vs before
autophosphorylation (233).
The mechanism of inhibition by substrates is not well understood
because; a) knowledge concerning receptor activation is still incomplete and b) few have attempted to define the mechanism.

Domains

involved in substrate binding and the number of substrate binding sites
per receptor are not known.

Shoelson et al. (248) showed that

inhibition of exogenous kinase activity by substrate analogues does not
involve competition with binding of ATP.

Data presented in chapter

three of this dissertation indicate that substrate inhibition by H2b
also does not involve competition with ATP.

Shoelson et a1. suggested

that tyrosine residues 1146, 1150 and 1151 of the insulin receptor are
in spatial proximity to the substrate binding portions of the kinase
catalytic active sites.

They hypothesized that binding of substrate

before ATP binding and phosphorylation prevents the transfer of
phosphate from ATP to the critical sites on the receptor, thereby
preventing activation.

Under these conditions the rate of exogenous
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substrate phosphorylation would be similar to the unactivated receptor.
If ATP binds before substrate, the transfer of phosphate to the
critical residues is unabated, resulting in activation of the kinase
before substrate binds.

Activation of the epidermal growth factor

receptor and pp60v-src kinases may also be inhibited by this same
mechanism (248).

Whether substrate inhibition is important in

regulation of insulin receptor tyrosine kinase activity in vivo is
unclear at this time.

x.

INSULIN RESISTANCE
Insulin resistance is a state in which a given level of the

hormone produces a subnormal effect.

Classically, insulin resistance

is defined either by the dose of insulin resulting in a half maximal
response or the maximal response achievable by the hormone.

An effect

on the dose eliciting half maximal effect is defined as a change in
sensitivity, while an altered maximal effect is defined as a change in
responsiveness

(125,126~.

Insulin resistance can occur at many levels

of insulin action including binding of the hormone to its receptor,
signal transduction by
events.

~he

receptor or at a plethora of post-receptor

Receptor defects include altered insulin binding (either

affinity or total number) and altered insulin receptor tyrosine kinase
activity.

These two types of insulin receptor defects can result in

decreased insulin sensitivity (a shift to the right in the
dose-response curve) or decreased responsiveness.

A decrease in the

binding affinity would be expected to result in decreased sensitivity
with unaltered responsiveness, while a decrease in the number of
binding sites would be expected to alter sensitivity and
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responsiveness.

However, in some cell types, including skeletal muscle

(159) and adipose tissue (149) only a small fraction of the total
number of receptors need to be occupied with hormone to elicit a
maximal effect (114).
receptors".

A

The unoccupied receptors are termed "spare

significant decrease in the total number of receptors

may not alter the responsiveness in these cells if the number of
receptors is still sufficient to elicit a maximal response.
A variety of clinical conditions and disease states are either a
result of or accompanied by insulin resistance.

These include obesity,

noninsulin-dependent diabetes mellitus (NIDDM), insulin dependent
diabetes mellitus (lDDM), sepsis, trauma and burns (Reviewed in
3,50,75,76,126,155,197,267,279).

In obese humans (6,36), obese rats

(158,198) and patients with NIDDM (6,34,78,189,251); decreased numbers
of receptors (34,35,78,158,251) (likely due to down regulation by
chronically elevated insulin levels) and/or defective insulin receptor
tyrosine kinase activity is observed (6,34,35,78_189,251).

The

mechanisms responsible for decreased kinase activity in NIDDM has been
addressed by two groups.

In one study Brillon et al. (24) compared the

precipitability with antiphosphotyrosine antibodies of
insulin-stimulated phosphorylated insulin receptors from liver of
patients without or with NIDDM.

Only -50% of the receptors from

patients with NIDDM were precipitated compared to -100% in controls.
Therefore two populations of receptors seem to exist in NIDDM, half of
them are kinase competent while the other half are not.
Kusser et a1. (189) showed

t~at

Obermaier-

defective in vitro autophosphorylation

and exogenous kinase activity of insulin receptors from skeletal muscle
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of patients with NIDDM was due to defective autophosphorylation at the
third critical site.
Most of the work described in this dissertation involves insulin
receptor function in insu1inopenic diabetes in rats (a model of IDDM).
Defects in insulin receptor kinase activity have been observed in
receptors isolated from muscle (32) and liver (123,195) of animals with
experimentally induced insulinopenic diabetes.

However, Amatruda et

ale (4) and Truglia et a1. (272) reported no effect of streptozotocin

(SIZ) induced-diabetes on insulin receptor autophosphorylation and
tyrosine kinase activity in liver or adipose tissue.

Furthermore Bak

et a1. (9) reported unaltered tyrosine kinase activity of insulin
receptors isolated from insulin resistant skeletal muscle of patients
with 100M.

Reported discrepancies in the effects of insulinopenia on

insulin receptor tyrosine kinase activity have been attributed to
different experimental protocols (discussed in chapters two, three and
four of this dissertation).

Much of the data was obtained from insulin

receptors solubilized from tissues with non-ionic detergents and
partially purified on WGA agarose.

Data presented in chapter two of

this dissertation indicates that activation of exogenous kinase
activity in vivo is decreased in skeletal muscle of insulinopenic rats
after insulin binding in vivo.

In a study by Burant et a1. (32)

separation of receptor subunits by SDS-PAGE revealed a subpopulation of
insulin receptor

e subunits

derived from muscles of STZ-diabetic rats

with decreased electrophoretic mobility.

After partial digestion with

V-B protease, differences between control and diabetic-derived subunits

became more evident.

Treatment with glycosidases suggested that excess
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sialylation may account in part for the altered mobility of diabetic
derived

a

subunits.

The altered mobility and altered kinase activity

were reversed by chronic insulin therapy.

Whether the ,structural

alteration is responsible for observed altered kinase activity is
unknown.

Data presented in chapter three address the mechanisms

responsible for the observed decreased activation of the liver insulin
receptor upon insulin binding in vitro.

These data suggest that

diabetes induced structural alterations render increased susceptibility
of the receptor tyrosine kinase to inhibition by the substrate H2b.
Data presented in chapter five suggest that the same mechanism occurs
in muscle in vitro.
Many hormones which act antagonistically to insulin produce an
insulin resistant state when present in supraphysiologic levels.

These

include catecholamines (86 t l97 267) glucagon (197,267) and glucocortit

colds (3,75,267).

A number of disease states are accompanied by

increased levels of these insulin-antagonists; including type 1
diabetes (50,67) sepsis and various states of trauma (279).
Catecholamine treatment of isolated human adipocytes was shown to
decrease both insulin binding affinity and insulin receptor autophosphorylation (86).

Glucocorticoids mayor may not affect insulin

binding, however even when present, altered binding does not account
for the observed insulin resistance (discussed in chapter two of this
dissertation).

A

study by Truglia et ale (272) and data presented in

chapter two of this dissertation (18) suggest that glucocorticoid
induced insulin resistance occurs at steps distal to the receptor.
Decreased insulin receptor tyrosine kinase activity has been
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observed in patients with familial forms of moderate to severe insulin
resistance including lipoatrophic diabetes (165) and type A insulin
resistance (91,92).

Defects in kinase activity in these syndromes has

been attributed to various mutations in the insulin receptor gene
(122,193,266,300).

The mechanisms responsible for defective tyrosine

kinase in these syndromes are probably different than those in NIDDM
and IDDM; as defects accompanying the latter two are aquired rather
than genetic, ie. they are corrected by normalization of altered
metabolism which accompanies these disease states (30,80,123).

XI.

S~Y

In summary, considerable advances in the understanding of insulin
receptor function have been accomplished in the past 15 years.

One of

the most important being the discovery of the insulin receptor tyrosine
kinase.

That the insulin receptor tyrosine kinase is important for

most, if not all of insulin's actions is fairly certain.

However,

definition of endogenous substrates for the kinase must be accomplished
before a complete understanding of the role of the insulin receptor
tyrosine kinase in insulin action can be achieved.

In addition the

role of the insulin receptor tyrosine kinase in various states of
insulin resistance is still unclear.

Studies in this dissertation

addressed the role of the insulin receptor tyrosine kinase in two
insulin resistant states.

These studies involved: 1) the role of the

insulin receptor in the insulin resistance of skeletal muscle
associated with hypercortisolemia (chapter two); 2) activation of the
skeletal muscle insulin receptor tyrosine kinase in vivo, and effects
of insulinopenic diabetes on the in vivo activation of the insulin
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receptor tyrosine kinase (chapter two); 3) structural differences
between the rat muscle and liver insulin receptor (chapter four); and
4) the mechanisms underlying defective in vitro insulin receptor
tyrosine kinase activity in liver (chapter three) and skeletal muscle
(chapter five) in insulinopenic diabetes.
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CHAPTER II
EFFECTS OF HYPERCORTISOLEMIA AND DIABETES
ON SKELETAL MUSCLE INSULIN RECEPTOR FUNCTION
IN VITRO AND IN VIVO

The contents of this chapter have been previously published in similar
form in Am. J. Physiol. 256:E39-E48, 1989.
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INTRODUCTION
Insulin resistance is characteristic of many disease states
including non-insulin dependent (NIDDM, type 2) diabetes (76),
uncontrolled insulin-dependent (IDDM,type 1) diabetes (30,58),
hypercortisolemia (3), obesity (76) and uremia (3).

Although various

defects in insulin action have been reported in these conditions, the
mechanisms involved have not been adequately defined.

Insulin's

actions are initiated upon insulin binding to its receptor, a
heterotetramer glycoprotein composed of two
linked by disulfide bonds (87,225).

a

and two

a

subunits

Insulin binding to the a subunit

induces a conformational change in the receptor resulting in
autophosphorylation on tyrosine residues of the S subunit.

Autophos-

phorylation on critical site(s) activates the insulin receptor
exogenous tyrosine kinase.

This activation is the first known event

upon insulin binding and is believed to mediate various biological
effects of insulin (reviewed in 87,225).
While insulin's effects are anabolic, those of the glucocorticoids
are largely catabolic (3,215).

Glucocorticoid excess is associated

with increased glucose production in liver (3); decreased peripheral
glucose transport and utilization (3,63,196,265,272); decreased protein
synthesis and increased protein degradation in muscle (215).

The

mechanism by which glucocorticoids antagonize the effects of insulin is
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poorly understood.

Alterations in insulin binding to its receptor have

been reported following administration of various glucocorticoids
(3,33,63,110,128,145,196,199), however the results vary with type of
glucocorticoid (63), length of administration (33,199), type of tissue
studied (199) and whether the glucocorticoid is administered in vivo or
in vitro (13,34).

No consistent correlation between alterations in

binding and altered insulin response has been observed in various
hypercortisolemic states, leading to the conclusion that a post-binding
mechanism is responsible for the insulin resistance (33,63,199,265).

A post-receptor defect has been demonstrated in adipocytes and
fibroblasts following dexamethasone administration involving increased
translocation of glucose transporters from the plasma membrane to
intracellular sites (reviewed in 110).

A recent study reported

unaltered in situ insulin receptor autophosphorylation and exogenous
kinase activity of solubilized insulin receptors from insulin resistant
adipocytes of dexamethasone treated rats (272).

Previous studies have

not investigated whether altered insulin receptor tyrosine kinase
activation occurs in muscle during hypercortisolemia.
Impaired insulin receptor kinase activation may play a role in the
insulin resistance of insulinopenic diabetes.

Insulin receptors

solubilized from liver (123,195) and muscle (30) of severely
insulinopenic diabetic rats show decreased basal and insulin stimulated
autophosphorylation and exogenous tyrosine kinase activation.
Furthermore, treatment of streptozotocin diabetic rats with insulin for
3 days improves insulin sensitivity in muscle (277), and restores
autophosphorylation and exogenous kinase activity of the muscle insulin
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receptor to control levels (30).

While decreased insulin receptor

kinase activity has been reported in various insulin resistant states
including insulinopenia (30,123,195), NIDDM (34,78), fasting (79) and
obesity (35,158), these reports are of solubilized receptors exposed to
insulin in vitro.

Insulin receptor kinase activation in vivo

has not

been investigated in any of these conditions.
Recently, methods have been described to assess the in vivo
activation state of the insulin receptor in intact cells (143) and
animals (29).

In the present study, we examined the activation of

muscle insulin receptors by

insulin administered in vivo to control

rats and to two rat models of insulin resistance:
diabetes and hypercortisolemia.

insulinopenic

We report that insulin stimulates the

muscle insulin receptor in vivo in a dose-dependent manner.
Streptozotocin diabetes results in decreased insulin stimulated
activation of the muscle insulin receptor kinase in vivo, and therefore
supports the data from in vitro studies.

Finally, insulin binding and

tyrosine kinase activation is unaltered in receptors isolated from
skeletal muscle of

hyp~rcortisolemic

rats after exposure to insulin in

vitro or in vivo, suggesting that glucocorticoids antagonize the
effects of insulin at steps distal to the receptor.

MATERIALS AND METHODS
Materials:

Streptozotocin was a gift from Upjohn Research Labora-

tories (Kalamazoo, MI).

Monocomponent, crystalline pork insulin was a

gift from Dr. Ronald Chance and monoiodinated Al4[125 I ]-insulin from
Dr. B. H. Frank and Dr. R. diMarchi, Lilly Research Laboratories
(Indianapolis, IN). Wheat germ agglutinin (WGA) was from Vector
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Laboratories (Burlingame, CA).

Cyanogen bromide (CNBr)-Sepharose 4B

beads were from Pharmacia Fine Chemicals (Piscataway, NJ).
was from FBA Pharmaceuticals (New York).

Aprotinin

Bacitracin was from Pfizer

(New York). y [32 p )ATP was prepared from [32P]orthophosphate (lCN,
Cambridge, MA) in Gammaprep vials (Promega Biotec, Madison, WI) as described by the manufacturer.

Electrophoresis reagents were from Serva

(Heidelberg, Federal Republic of Germany) and the apparatus was from
LKB Instruments, Inc. (Houston, TX).

Autoradiography film, X-Omat AR

was from Eastman Kodak Co. (Rochester, NY).

Lightening + intensifying

screens were from Dupont Co. (Wilmington, DE).

All other reagents and

chemicals were from Sigma Chemical Co. (St. Louis, MO) unless
otherwise specified.
Animals:

Male Wistar (WI) BR rats (Charles River Laboratories,

Wilmington, MA) weighing 100-160 g were allowed access to standard
rodent chow and water ad libitum.

Food was withdrawn -10 hours before

experimentation with the exception of experiments using diabetic rats
where controls and diabetics were allowed access to food ad libitum.
Diabetes was induced with streptozotocin in citrate buffer, pH 4.5,
administered intraperitoneally in a single dose of 120 mg/kg body
weight to overnight fasted rats.
after streptozotocin injection.
injected

Diabetic rats were studied 7 days
For glucocorticoid studies, rats were

daily at - 10:00 a.m. with a cortisone acetate suspension

(Cortone, Merck Sharp & Dohme, West Point, PA) administered subcutaneously at a dose of 10 mg/100 g body weight for 5 days.

This dose of

cortisone results in plasma glucocorticoid concentrations similar to
those observed in rats during severe stress (215).

Control rats were
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given an equal volume of saline.

Glycosuria was monitored by TesTape

(Eli Lilly Co.) and was 4+ in diabetic rats.

Plasma glucose levels

were determined with a Beckman Glucose Analyzer 2 (Beckman Instrument
Co., Palo Alto, CA) on blood samples obtained when the animals were
killed.

Plasma insulin levels were measured by double antibody

radioimmunoassay (83) using both rat insulin and human recombinant
insulin as standards where appropriate.
Insulin receptor isolation:

For studies involving receptor

activation in vitro, frozen muscles were powdered, homogenized and
insulin receptors were solubilized and partially purified on YGA as
described previously (29).

For experiments involving in vivo

activation, receptors were isolated by one of two methods as described
previously (29,32) with minor modifications.

In method A, frozen

hindlimb muscles were powdered and homogenized in 50 roM Hepes l , pH 7.4,
1% Triton X-100, 1 trypsin inhibitory unit/ml aprotinin, 5 mM EDTA, 10

mM NaF, 10 roM sodium pyrophosphate, 1.5 mg/ml bacitracin, 100 uK Na3V04
and 2 mM phenylmethy1su1fonyl fluoride.

After centrifugation at

10,000 x g for 10 min, the supernatant was centrifuged at 150,000 x g
for 90 min.

The supernatant was then applied to a YGA column pre-

equilibrated with 50 roM Hepes, pH 7.4, 0.1% Triton X-IOO, 5 mM EDTA, 10
mM NaF, 10 roM sodium pyrophosphate and 100 uM Na3V04.

The column was

washed with 25 bed volumes of the same buffer and glycoproteins were
eluted with this buffer supplemented with 0.3 M N-acetylglucosamine.
This method was used in all experiments where the in vivo kinase
activation assay was carried out using receptors adsorbed to insulinagarose beads.

In method B, receptors were isolated as in method A
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except that the WGA colunmn was washed with 50 mM Hepes, 0.1% Triton X100, 100 uK Na3V04, pH 7.4 and glycoproteins were eluted with this
buffer supplemented with 0.3 M N-acetylglucosamine.
isolation, WGA eluates were used within 24 hrs.

Fo~lowing

receptor

This method was used

in the experiments shown in Fig. 7, and was validated previously in our
laboratory (32).

All receptor preparations were separated into

aliquots and stored frozen at -80 0 C until further use.
Insulin binding:

Insulin binding was performed as described

previously (30) using A14[125 I ] insulin (- 0.09 nM, 300 uCi/ug) without
or with increasing concentrations of unlabeled insulin (1-10,000
ng/ml).

Binding at 10,000 ng/m1 unlabelled insulin was subtracted as

nonspecific in all binding studies.

All kinase assays were carried out

using equal insulin binding activities from WGA eluates, determined by
the ratio of specific binding between individual receptor preparations
at several insulin concentrations as described previously (30).
In vitro exogenous substrate kinase and autophosphorylation
assays:

For assays of kinase activity in vitro, two exogenous

substrates were used: the synthetic copolymer poly glu-tyr (4:1) or
histone H2b.

For assays with poly glu-tyr, receptor preparations (- 25

fmole insulin binding activity) were incubated without or with
increasing concentrations of insulin (1 to 100 nM) in buffer containing
50 roM Hepes, pH 7.4, 5mM MnC12' 12 roM MgCl2' 0.05% bovine serum albumin
(BSA) and 3 mg/mi poly glu-tyr (4:1) for 45 min at 25 0 C.
then chilled to 4 0 C.
uK

Samples were

Phosphorylation was initiated by addition of 100

Y [32 p ]ATP (1 uCi/nmole).

Reactions were allowed to proceed for 45

min at 4 0 C and were stopped by addition of 50 roM unlabelled ATP.
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Aliquots were spotted onto Whatmann 3MM filter paper and dropped into
an ice cold solution of 10% trichloroacetic acid (TCA) and 10 roM
Na4P207'

Papers were then washed 3 times with 10% TCA 10 mM Na4P207

at 25 0 C, dried, and 32p quantified by scintillation spectrophotometry.
Samples without substrate were assayed in parallel and subtracted from
samples with added substrate.

A lag phase (- 10 min) was observed

before exogenous substrate phosphorylation was linear; the lag phase
was established to be identical for receptors from experimental groups
and controls and presumably represents the time required for activation
of the exogenous kinase at 4 0 C.

For in vitro studies of

Bsubunit

autophosphorylation and exogenous kinase assays using histone H2b as
the substrate, assay conditions were as described below for in vivo
experiments, except that receptors (- 25 fmol) were incubated without
or with 10- 7 M insulin instead of insulin agarose' prior to kinase
assays and ATP concentration was 25 uK (25 uCijnmole).

All experiments

were performed under conditions where assays were linear with regard to
receptor concentration and time.
Assays of kinase activation in vivo:

In the first set of experi-

ments control rats were anesthetized with methoxyfluorane (Me to fane ,
Pitman-Moore, Washington Crossing, N.J.) and injected via tail vein
with saline or increasing doses of human insulin (Humulin, recombinant
DNA origin, Eli Lilly, Indianapolis, IN).

In subsequent experiments,

control and diabetic, or control and cortisone acetate treated
(glucocorticoid, GLX) rats were injected via tail vein with either
saline or a single dose of insulin (0.10-0.11 Uj10a g or 5 Ujrat).
Five min after injection, hindlimb muscles (gastrocnemius and soleus)
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were frozen in situ with Wollenberger tongs precooled in liquid
nitrogen and receptors isolated as decribed in the in vivo isolation
procedure.

Kinase assays were performed as described by Burant et ale

(29,32) with minor modifications.

In method A, receptors (- 100 fmole)

isolated by the in vivo isolation method A were incubated for 20 min at
25°C with insulin agarose (prepared as described by Yu and Czech,
(303).

Phosphatase and kinase inhibitors were then removed by washing

once with buffer containing 50 roM Hepes, pH 7.4, 0.1% Triton X-lOO and
50 roM NaCl, and then twice with buffer containing 50 roM Hepes, pH 7.4
and 0.1% Triton X-100.

5 roM MnC12 , 0.05% BSA and Histone H2b (1

mg/ml), were then added in buffer containing 50 roM Hepes, 0.1% Triton
X-lOO, pH 7.4, and phosphorylation initiated with addition of 2.5 uK Y
[32 p ]-ATP (50 uCi/nmole).

This concentration of ATP is sufficient to

support the transfer of phosphate from ATP to the substrate but is
insufficient to further activate the receptor's exogenous kinase (303),
thereby preventing activation in vitro.

Reactions were allowed to

proceed for 4 min at 25 0 C and stopped by the addition of 4X Laemm1i's
sample buffer

supplemen~ed

concentration).

with 5% 2-mercaptoethanol (final

Samples were then placed in boiling water for 3 min.

Proteins were separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) with a 5-19% polyacrylamide gradient.

Gels

were digested with 1 N NaOH at 55 0 C for 1 hour to hydrolyze serine
and threonine phosphates (11).

Histone H2B and the 8

subunit of the

insulin receptor were localized by autoradiography, excised from dried
gels, digested in 30% H202 and 32p counted by scintillation spectrophotometry.

An area of the gel determined to be free of

42

phosphoproteins, equivalent to the size of the excised bands was also
excised, digested, counted and subtracted as background.
In method B, receptors were isolated by the in vivo isolation
method B.

Receptors were incubated without or with 10-7M insulin in

buffer containing 50 roM Hepes, pH 7.4, 0.1% Triton X-IOO, 5 roM MnC12,

0.05% BSA and 100 uK Na3V04.
histone H2b as substrate.

Kinase assays were performed using

Reaction conditions were identical to those

described for the in vitro assays using this substrate.

This allowed

for the comparison of exogenous kinase activity after maximal
activation in vitro with that obtained after maximal activation in
vivo.
All kinase assays were performed under conditions in which <10% of
ATP was hydrolyzed.

ATPase activity of individual receptor

preparations was determined by measuring orthophosphate and ATP by high
performance liquid chromatography before and after kinase assays as
described previously (30).
Others:

Hindlimb muscle DNA was quantified using a modification

of the Burton assay (281).

Statistical analyses were performed by

Students t test.
RESULTS
Animal characteristics:

Table 1 summarizes the body weights,

plasma glucose and plasma insulin levels of rats in all studies.

Rats

rendered diabetic by streptozotocin were markedly hyperglycemic and
hypoinsulinemic and gained little or no weight over the 7 days.

Rats

injected with cortisone acetate either lost or failed to gain weight
following the first day of injection.

fasting plasma glucose and
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insulin levels in cortisone treated rats were 236 ± 15 mg/dl and 81 ±
11 uU/ml respectively, compared to a

~asting

plasma glucose of 146 ± 7

mg/dl and a fasting plasma insulin of 11 + 3 uU/ml in controls,
indicating insulin resistance in the hypercortisolemic rats.
Insulin binding to solubilized receptors:

When subjected to

Scatchard analysis (Fig 1) curvilinear plots were obtained with
receptors from control and cortisone treated rats.

No difference in

the insulin binding affinity between the two groups was apparent.
When expressed per g muscle, there appeared to be -30% increase in
total number of receptors (by extrapolating to the X intercept of the
curve) from cortisone treated rats as compared to controls.

Since

hypercortisolemia results in decreased muscle protein, we measured
muscle DNA concentrations as an indication of muscle cell number.
Hindlimb muscle (primarily gastrocnemius) DNA was significantly
increased (851 + 49 ug/g muscle tissue) in cortisone treated ratscompared to controls (662 ± 30 ug/g, n - 6 rats/group) (p < 0.01).
Therefore, when receptor number was calculated per muscle cell, there
was no difference in receptor number between cortisone treated rats and
controls.

There was an -2 fold increase in receptor number per g

hindlimb muscle in diabetic rats compared to controls with no apparent
change in insulin binding affinity confirming previous results (30)
from our laboratory (data not shown).
measured in control and diabetic rats.

Hindlimb muscle DNA was also
Hindlimb muscle DNA was

significantly increased (880 + 52 ug/g muscle tissue) in diabetic rats
compared to controls (650 + 20 ug/g, n = 6 rats/group) (p < 0.01).
Therefore, when receptor number was calculated per muscle cell, it was
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increased by - 50% in diabetic rats vs controls.

No difference in

number or insulin binding affinity was observed between receptors
isolated from rat muscles 5 min after i.v. injections of insulin or
saline (data not shown).
In vitro autophosphorylation and exogenous substrate kinase
activity of receptors isolated from control and cortisone treated rats:
When receptors isolated from muscles of control or cortisone treated
rats were incubated without insulin, very little 32p was incorporated
into the Bsubunit of the receptors or into the exogenous substrate
histone H2b.

When incubated with insulin, a -4 fold increase in 32p

incorporation into the 8 subunit of the receptor and histone H2b
occurred with receptors isolated from muscles of control and cortisone
treated rats.

No significant difference in basal or insulin stimulated

autophosphorylation (Fig. 2A) or H2b phosphorylation (Fig. 2B) was
observed between receptors isolated from control rats or rats treated
with cortisone.

We also investigated whether similar results would be

observed with another exogenous substrate, poly glu-tyr (4:1).

Equal

insulin binding activities of receptors isolated from control and
cortisone treated rats were incubated without or with increasing concentrations of insulin (10. 9 - 10- 7 M).

An insulin dose-dependent

increase in incorporation of 32p into the synthetic substrate poly gIutyr (4:1) was observed with receptors isolated from both control and
cortisone treated rats (Fig. 3), with half maximal activation occuring
at -1.3 X 10- 9 M insulin in both groups.

The kinase activity towards

this substrate was not significantly different between receptors
isolated from control and cortisone treated rats at any insulin
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concentration.
Insulin dependent activation of the insulin receptor kinase in
vivo:

We examined whether insulin administration to the intact rat

would result in dose-dependent activation of the muscle insulin
receptor tyrosine kinase.

A representative autoradiogram of 6 subunit

autophosphorylation and H2b phosphorylation following saline or
increasing doses of insulin (0.05, 0.1, 0.5, and 1 unit/IOO grams) i.v.
is shown in Fig. 4.

Insulin administration in vivo resulted in a dose-

dependent increase in the amount of phosphate incorporated into the

B

subunit of the receptor and into histone H2b although the effect of
insulin was much greater on H2b than on the receptor.

The results of

H2b phosphorylation and B subunit autophosphorylation are summarized in
Fig. SA and circulating insulin concentrations achieved at each dose of
insulin are shown in Fig. SB.

The phosphorylation of H2b is plotted as

a function of circulating plasma insulin concentration in Fig. SC.
Half maximal and maximal activation of the receptor exogenous kinase
were observed 5 min after 0.1 and 0.5 U insulin/lOO g respectively corresponding to circulating plasma insulin concentrations of 7.9
and 84 + 8 oM respectively.

±

0.72nM

These levels of insulin are approximately

10 times higher than levels required for half maximal and maximal
glucose transport in muscle in the intact rat (29).
In vivo activation in control and cortisone treated rats:

When

kinase activity was assayed after adsorption of receptors to insulinagarose (in vivo method A) no significant difference in kinase activity
towards H2b (Fig. 6A) or the

B subunit of the receptor (Fig 6B) was

observed between cortisone treated rats and controls at basal insulin
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levels (after injection of saline) or after i.v. injection of a half
maximally activating dose of insulin (0.1 U/lOO g).

Circulating

insulin concentrations 5 min after insulin injection were not
significantly different between controls (6.0 + 0.53 oM) and treated
(5.2 ± 0.52 riM) rats.
In a separate set of experiments rats were injected with either
saline or SU insulin/rat and in vivo kinase activity assessed by method
B (Fig. 7).

Using this method, we observed a significant increase in

basal kinase activity (after saline injection) towards histone H2b of
receptors isolated from cortisone treated rats, which presumably
reflects their increased fasting plasma insulin concentrations (Table
1) and the greater sensitivity of the assay.

Again. no significant

difference in kinase activity of receptors isolated from control or
cortisone treated rats was observed after injection of insulin.
Receptors fully activated with insulin in vivo were -90% active
compared to the same receptors which were further activated with a
maximally activating concentration of insulin in vitro (Fig 7) similar
to previous reports from our laboratory (7).

Similar results were

obtained using poly glu-tyr (4:1) as substrate (data not shown).
There was no significant difference in the amount of phosphate incorporated into the 8 subunits of the receptors isolated from control or
cortisone treated rats using this method (data not shown).
In vivo activation in control and diabetic rats:

Saline, or a

half maximally activating dose of insulin (0.1 U/lOO g) or a
supramaximally activating dose of insulin (5 U/rat) was injected via
tail vein to control or diabetic rats.

A representative autoradiogram
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of histone H2b and

e subunit

phosphorylation after a half maximally

activating dose of insulin in vivo is shown in Fig. 8.

Quantification

of results obtained with both doses of insulin is shown in Fig. 9.
Receptors isolated in their activated state from diabetic rats showed a
significant, S2% (p < 0.01) or 40% (p < 0.05), decrease in kinase
activity toward H2b 5 min after i.v. insulin administration of 0.1
U/100g or SU/rat respectively compared to receptors isolated from
insulin treated controls (Fig. 9A).
into the

B

In vitro phosphate incorporation

subunit of the receptor was also significantly lower in

receptors isolated from diabetic rats compared to controls after
exposure to insulin in vivo.

Receptors isolated from diabetic rats

incorporated 44% (p < 0.01) or 60% (p < 0.025) less phosphate than
equal numbers of insulin receptors isolated from controls after i.v.
insulin administration of 0.1 U/lOOg or SU/rat respectively (Fig 9B).
No significant difference in kinase activity towards histone H2b or
phosphate incorporated into the B subunit was observed between receptors isolated from the two groups at basal insulin levels.

Circulating

plasma insulin concentrations were not significantly different between
control (7.9 + 2.1 riM) and diabetic (7.6 + 2.0 tiM) rats after injection
of the half maximally activating dose.

After injection of the

supramaximally activating dose, circulating insulin concentrations were
significantly higher in diabetic (444

±

52 riM) vs. control (238

±

8 nM;

P < 0.025) rats, because all rats received the same amount of insulin
and the diabetics weighed less than controls (Table 1).

Since the

differences in insulin receptor tyrosine kinase activities observed in
these assays could have been due to variability in the proportion of
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receptors adsorbed to the insulin-agarose, binding assays were
performed on the supernatants after adsorption.

Less than 5% of the

receptors added to the insulin agarose were recovered in the
supernatants with no significant difference between control and
diabetic derived receptors.

DISCUSSION
Insulin receptor tyrosine kinase activation occurs in response to
insulin in purified receptor preparations (95,303), and in vivo

(29,32,95,143).

An insulin dose-dependent activation of the insulin

receptor kinase has been established in solubilized receptors and in
isolated intact adipocytes (143).

Studies in our laboratory reported

activation of the muscle insulin receptor kinase in intact rats
following a single bolus injection of insulin i.v. (29,32).

In the

present study we further demonstrate that the muscle insulin receptor
tyrosine kinase is activated in a dose-dependent manner following·
insulin administration in the intact rat.

In our system, half maximal

and maximal activation of the muscle insulin receptor tyrosine kinase
in the intact rat occured at circulating insulin levels of -8 X 10- 9 M
and -8.7 X 10- 8 M respectively.

These are ~10 and -20 fold higher than

levels which result in half maximal and maximal glucose transport in
muscles of intact rats using the euglycemic clamp technique (152) and
in isolated rat solei (159) respectively.

Glucose transport is not

directly coupled to receptor occupancy in rat soleus muscle (159)
indicating that muscle contains spare receptors.

This may explain the

discrepancy between in vivo glucose transport and in vivo kinase
activation in muscle, as it has been shown in Fao hepatoma cells (95)
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and isolated adipocytes (143), that insulin receptor autophosphoryla·
tion and exogenous substrate kinase activation correlates more closely
with receptor occupancy than with the concentration of insulin which
elicits biological effects.

In muscle, half maximal binding to

isolated solei occurred at insulin levels of 10. 8 M (159,302) and 4 X
10 -9 M (94) which are close to the levels which we report for half
maximal· activation of the muscle insulin receptor kinase in vivo.
However, caution must be taken in attributing our results solely to the
existence of spare receptors because in euglycemic clamp experiments
samples are taken after the first hour of insulin infusion (152).

Our

observation that supraphysiological levels of insulin were necessary to
fully activate the receptor after a 5 min bolus could be due to lack of
sufficient time for equilibrium binding of insulin.

Recently,

significant activation of the muscle insulin receptor kinase at
physiological levels of insulin was reported using euglycemic clamp
techniques in rats (26), with half maximal activation at 330 uU/ml
(-2.1 X 10- 9 M) insulin.
a prior insulin exposure.

Also, insulin's effects .can be potentiated by
In rat epitrochlearis muscle exposed to

supraphysiologic levels of insulin (20,000 uU/ml, -1.25 X 10- 7 M),
maximal glucose transport was obtained in 15 min whereas a similar rate
of transport was achieved at a physiological level (50 uU/m1, -3.1 X
lO-lOM) only after a much longer exposure time (301).

Similarly,

higher rates of glucose transport are achieved over time in euglycemic
clamp studies (152,301).

Therefore whether the lower dose of insulin

required for half-maximal activation of the insulin receptor kinase
using the clamp technique reflects equilibrium binding or a
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potentiating effect of long exposure to insulin is unknown.

Since in

isolated adipocytes, internalized activated receptors are dephosphorylated more rapidly than non-internalized activated receptors
(144), we killed the rats 5 min after insulin injection to minimize
internalization and therefore possible dephosphorylation of the insulin
receptor after activation (in adipocytes t 1/2 for receptor internalization is < 10 min (146».
Autophosphory1ation of the receptor was still detectable in our in
vivo assay even though we utilized conditions which we had previously
determined did not activate the receptor's exogenous kinase (29,32 and
data not shown).

Phosphorylation of the receptor can occur without

activation if conditions prohibit phosphorylation of critical sites on
the receptor (32,143,303).

Autophosphorylation in this assay may

reflect the S subunits of the receptors serving as in vitro substrates
for the in vivo activated receptor.

Whether this occurs intra- or

intermolecu1ar1y or both is not known.

Quantitatively however, the

insulin effect on phosphate incorporation into histone-H2b was greater
than on the in vitro 8 subunit phosphorylation in the "in vivo
activation" assay.

Autophosphorylation was detectable even after the

receptor was maximally activated in vivo.

This is similar to what

occurred in isolated adipocytes (143) and suggests that certain tyrosines on the receptor which seem not to be required for activation, are
not accessible in vivo but can be phosphorylated in vitro.
Insulin receptor kinase activity has been shown to be decreased in
receptors solubilized from muscle (30) and liver (123,195) of rats
rendered diabetic with streptozotocin.

Studies of other insulin
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resistant states including patients with NIDDM (34 78) obese humans
t

(35) and obese rats (158) have reported similar decreases in exogenous
kinase activity of solubilized muscle (35,158), adipose tissue (78) and
liver (34) receptors after insulin binding in vitro.

Note however,

that discrepant observations have also been reported in several of the
conditions listed above (discussed in 30,35,87).

In the streptozotocin

diabetic rat model, insulin receptor autophosphorylation was also
reported to be increased (17) or unchanged (4,272) in solubilized
receptors from liver (4 t 17) and adipocytes (272).

Furthermore,

exogenous kinase activity towards the substrate poly glu-tyr (4:1) was
unaltered (272) in receptors solubilized from insulin resistant
adipocytes from streptozotocin diabetic rats.
discrepancies are not clear.

The reason(s) for these

In addition to possible methodological

differences in receptor preparation, variables include the use of
different tissues, differences in the duration or degree of diabetes
and the use of different substrates to measure exogenous kinase
activity as discussed below.
Metabolic effects on the insulin receptor may be tissue specific.
Altered insulin receptor kinase activity has been reported in obese
humans without or with NIDDM, but the effects varied with the type of
tissue studied.

Caro et a1. (34) and Freidenberg et a1. (78) reported

mild (34) or no (78) effects of obesity on the kinase activity of liver
or adipocyte derived receptors while insulin receptors derived from
skeletal muscle (35) of similar obese patients were resistant to
exogenous tyrosine kinase activation by insulin.

In addition, the

tyrosine kinase activity of insulin receptors derived from liver or
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adipocytes of obese patients with NIDDM was decreased when compared to
obese patients without NIDDM (34,78) while this was not observed in
receptors derived from skeletal muscle (35).

Insulin resistance has

been related to the duration of the insulinopenia in rats (178) and to
the degree of control of diabetes in humans with IDDM (30).

It is

therefore possible that the time after induction of diabetes or
differences in the severity of the metabolic alterations elicited by
different research protocols affect the observed receptor kinase activities.

In studies of liver derived insulin receptors Blackshear et

a1. (17) reported increased autophosphorylation of the insulin receptor
48 hours after administration of streptozotocin; Amatruda et al. (4)
reported no effect on the kinase 7-21 days after streptozotocin
treatment which resulted in

nonketotic diabetes; Okamoto et a1. (195)

on the other hand, found decreased exogenous kinase activity 5 weeks
following induction of diabetes and furthermore, found a larger
decrease in severely diabetic rats compared to mildly diabetic rats.
The rats which we studied were severely diabetic indicated by
undetectable insulin levels and no weight gain.

Finally, laboratories

examining exogenous kinase activity of diabetic derived insulin
receptors compared to controls used different substrates as
phosphoacceptors.

Substrate specific effects have already been

reported in some insulin resistant states since decreases in exogenous
substrate kinase activities have been observed without concomittant
decreases in receptor autophosphorylation (34,35,78,79).

This under-

scores the need for defining the endogenous substrate(s) of the insulin
receptor kinase and examining their

rec~ptor

mediated phosphorylation
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in insulin resistant states.
It has been suggested that defective tyrosine kinase activity may
contribute to insulin resistance although insulin receptor tyrosine
kinase activation in vivo had not been previously investigated in any
of these conditions.

Our results indicate that following induction of

streptozotocin diabetes in rats, activation of the muscle insulin
receptor kinase is impaired upon insulin binding in vivo.

These

results, therefore, further support the hypothesis that altered insulin
receptor kinase activation could contribute to the insulin resistance
observed in severe, uncontrolled insulinopenic diabetes.

Since the

number of receptors per muscle cell was increased - 50% in rats with
insulinopenic diabetes, the reduction in kinase activity per receptor
may have limited biological significance if phosphorylation of the
endogenous substrate(s) of the insulin receptor kinase parallels that
of the model substrate used.

The answer to these questions awaits

definition of the endogenous substrate(s) of the insulin receptor
tyrosine kinase.
Our in vivo assay utilizing adsorption to insulin agarose did not
detect differences in basal kinase activity between control and
diabetic rats or between control and glucocorticoid treated rats
despite the fact that circulating basal insulin levels were nearly
undetectable in diabetics and were nearly twice as high in cortisone
treated rats compared to controls.

This is probably due to limitations

in the sensitivity of this assay and the relatively large variance of
measurement.

When assayed without adsorption to the beads, we did

detect a small but significant increase in basal kinase activity of
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receptors isolated from glucocorticoid treated rats compared to controls.

Using both methods, there was no significant difference in

kinase activation by exogenously administered insulin.

Our results

indicate that in vivo administration of cortisone to rats has no
significant effect on insulin receptor number or insulin binding
affinity of solubilized muscle insulin receptors.

Similarly, cortico·

sterone· in vitro did not affect insulin binding to mouse solei (265).
In a number of tissues increased circulating insulin results in down
regulation of the insulin receptor while decreased circulating insulin
levels result in up-regulation of the the insulin receptor
(30,123,195).

It is interesting that despite increased circulating

insulin levels, the total number of receptors isolated from muscles of
cortisone treated rats was not decreased compared to controls.

Ad-

ministration of glucocorticoids to rats results in depressed insulin
binding in adipocytes and hepatocytes (199) presumably due to down
regulation caused by increased circulating insulin levels, or as
suggested in studies of rat liver membranes due to decreased insulin
binding affinity with no change in receptor number (128).

In

preliminary studies we found a decrease in the number of insulin
receptors isolated from liver in the same rats in which no change in
insulin receptor number was found in muscle (data not shown).

Dexa-

methasone stimulates the synthesis of insulin receptors in IM9
lymphocytes (72) and in cultured rat hepatocytes (234) and increases
insulin receptor mRNA in IM9 lymphocytes (176).

Chronic exposure of

3T3 mouse fibroblasts to dexamethasone results in increased receptor
number due to decreased receptor degradation with no change in receptor
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synthesis (145).

Thus, any down regulation due to increased

circulating insulin levels could be offset in muscle by possible
effects of glucocorticoids on receptor synthesis and/or degradation.
Since glucocorticoids affect mUltiple insulin sensitive pathways
in muscle: glucose transport, amino acid transport, protein synthesis
and protein degradation, we postulated that excess glucocorticoids may
exert their effects by modulating insulin receptor tyrosine kinase
activation.

In the present study under conditions, where

glucocorticoid induced insulin resistance was quite evident, there was
no detectable impairment of muscle insulin receptor tyrosine kinase
activation.

Our results are in agreement with those of Truglia et a1.

(72) who found no effect of dexamethasone administration to rats on the
autophosphorylation of the insulin receptor in situ or on the exogenous
kinase activity of receptors solubilized from insulin resistant
adipocytes.

Whether or not glucocorticoids in combination with other

factors may contribute to the insulin receptor tyrosine kinase defect
observed in some conditions is unknown.

Our data suggests that in

muscle the insulin resistance associated with glucocorticoid excess is
a post-receptor defect.
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Table 1.

Body Weights, Glucose and Insulin Levels

Initial
B.W.

Final
B.W.

Plasma
Glucose
(mg/dl)

Plasma
Insulin
(uU/ml)

Control

126+2 (11)

156+4(10)

146+7(15)

11+3(7)

Cortisone

132+1(11)

124+2(10)*

236+15(14)*

81+11(7)*

Control

118+2(12)

160+2(12)

162±6(6)

43+7(6)

Diabetic

116+2(12)

115+3(12)*

346±17(6)*

Values are means + S.E.M.; numbers in parentheses
rats/treatment group. *p < 0.05 vs control.

~

0.1+0.02(6)*

number of
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Figure 1.

Scatchard plot of 125I-insulin binding to solubilized,

WGA-purified insulin receptors.

WGA eluates (25 ul) from skeletal

muscle of control or cortisone treated (GLX) rats were incubated with
trace A14[l25 I ]insulin in a total volume of 200 ul, with buffer
containing 50 mM Hepes, 100 mM NaCl, 0.05 mg/ml bovine serum albumin,
0.1% Triton X-lOO and 0.075 M N-acetylglucosamine, pH 7.8, for 16 h at
4°C.

The receptor and bound insulin were precipitated by sequential

addition of 100 ul of 0.3% bovine gamma globulin and 300 ul of 25%
polyethylene glycol.

Radioactivity precipitated in the presence of

10,000 ng/ml unlabeled insulin was subtracted from each point as
nonspecific binding.
used.

Binding data were normalized to weight of tissue

Each point is the mean + SE of six receptor preparations.
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Figure 2.

Autophosphorylation (A) and histone kinase activity (B)

of solubilized insulin receptors activated in vitro.

Equal insulin

binding activities of receptors from control or cortisone

tre~ted

(GLX)

rats were incubated with histone H2b, without or with lO-7 M insulin as
described under "Materials and Methods".

Phosphorylation was initiated

by addition of 25 uM y[32 p ]ATP (25 uCi/nmole) and after 4 min at 2S oC
reactions were stopped by addition of 4 times concentrated Laemmli's
sample buffer.

Samples were separated by SDS-PAGE and after hydrolysis

of stained gels with 1 N NaOH for 1 hr at 55°C, 8 subunit and histone
bands were localized by autoradiography.

After excision of bands

radioactivity was determined by scintillation spectrometry.
means + SE for three different receptor preparations.
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Figure 3.

Dose response of poly glu-tyr (4:1) kinase activity of

solubilized insulin receptor activated with insulin in vitro.

Equal

insulin binding activities of receptors isolated from muscles of
control and cortisone treated (GLX) rats were incubated at 25 0 C with
poly glu-tyr (4:1) without or with increasing concentrations of insulin
(10- 9 - lO-7M) in buffer containing 5 mM MnC12 and 12 mM MgCl2, 50 mM
Hepes, 0.1% Triton X-100, 0.05% BSA, pH 7.4 as described under
"Materials and Methods".

Phosphorylation was initiated by addition of

100 uM y[32 p ]ATP (1 uCi/nmole) and reactions stopped after 45 min at
4°C by addition of 50 mM unlabelled ATP.

Aliquots were spotted onto

Whattman 3MM paper, precipitated by an ice cold solution of 10% TCA, 10
roM Na4P207 and washed as described under "Materials and Methods".

Radioactivity on papers was determined by scintillation spectrometry.
Values are Means + SE for 4 receptor preparations.
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Figure 4.

Autoradiogram of 8 subunit and histone H2b phosphory-

lation by receptors solubilized after activation with insulin in vivo.
Control rats were anesthetized and injected with saline or increasing
doses of insulin (.OS - 1.0 U/lOO g) via tail vein and receptors were
isolated after 5 min in their in vivo activation state (method A) as
described in ftMaterials and Methods".

Equal insulin binding activities

of receptors were adsorbed to insulin-agarose and washed as described
in "Materials and Methods".

After addition of 1 mg/ml histone H2b, and

S mM MnC12 in a buffer containing 50 mM Hepes, 0.1% Triton X-lOa 0.05%
BSA pH 7.4, kinase reactions were initiated by addition of 2.5 uK Y
[32 p ]ATP (50 uCi/nmole) and stopped after 4 min at 2SoC by addition of
4 times concentrated Laemmli's sample buffer.

Samples were then

separated by SDS-PAGE, and gels were hydrolyzed with 1 N NaOH at 5SoC
for 1 hr.
dried gels.

8 subunit and H2b bands were localized by autoradiography of

The single arrow indicates the 8 subunit band and the

double arrows indicate the location of histone H2b.
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Figure 5.

Histone H2b and

8 subunit phosphorylation by receptors

activated with insulin in vivo.

Anesthetized control rats were

injected with increasing doses of insulin via tail vein.
after injection

t

Five min

receptors were isolated and kinase assays performed as

described in legend to Fig. 4.

After autoradiography,

B subunit and

histone H2b bands were excised from gels and radioactivity was
determined as described in "Materials and Methods".
activity towards histone H2b and
function of insulin dose.

B.

A.

Kinase

B subunit phosphorylation as a
Circulating plasma insulin con-

centrations as a function of insulin dose.

C.

Kinase activity towards

histone H2b plotted as a function of circulating plasma insulin
concentration.

Insulin doses were 0, 0.05, 0.1, 0.5 and 1.0 U/100 g

which corresponds to doses of 0, 1923, 3846, 19,230 and 38,460 ng/100 g
respectively (1 ng - 26 uU).

Each point is the mean ± SE for 4 rats.
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Figure 6.

Effect of cortisone treatment on insulin receptor

activation by a half maximally activating dose of insulin in vivo.
Control or cortisone treated (GLX) rats were injected with saline or a
half maximally activating dose of insulin (0.10 - 0.11 U/100 g) via
tail vein.

Five min after injection receptors were isolated and their

in vivo kinase activity measured as described in legend to Figs. 4 and
5.

A.

Kinase activity towards histone H2b.

incorporated into the

B subunit

means + SE for 8-9 rats/group.

B.

Phosphate

of the insulin receptor.

Values are
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Figure 7.

Effect of cortisone treatment on insulin receptor

activation by a supramaximally activating dose of insulin in vivo.
Control or cortisone treated (GLX) rats were injected with saline or SU
insulin via tail vein and receptors were isolated after S min in their
in vivo activation state (method B) as described in "Materials and
Methods".

Equal insulin binding activities of receptors were incubated

without or with 10- 7M insulin, in buffer containing 5 mM MnCl2, O.OS%
BSA, 50 mM Hepes, 0.1% Triton X-IOO and 100 uK Na3V04, pH 7.4 for 20
minutes at 25 0 C.

After incubation for 10 min. at 2SoC with H2b (0.4

mg/ml), phosphorylation was initiated by addition of 25 uM Y [32 p ]ATP
(25 uCi/nmole) and after 4 min at 2S o C reactions were stopped by
addition of 4 times concentrated Laemmli's sample buffer.

Samples were

separated by SDS-PAGE and after hydrolysis of stained gels with IN
NaOH for 1 hr at 55°C, histone bands were localized by autoradiography
of dried gels.

After excision of bands radioactivity was determined by

scintillation spectrometry.
*p < O.OS vs control.

£ach point is the mean + SE for 4 rats.
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Figure 8.

Autoradiogram showing

a subunit

and histone H2b

phosphorylation by receptors isolated from control or diabetic rats
after activation with a half maximally activating dose of insulin (0.1

UllOa g) in vivo.

The single arrow indicates the

a

subunit band and

the double arrows indicate the location of histone H2b.
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Figure 9.
vivo.

Effect of diabetes on insulin receptor activation in

Anesthetized control or diabetic rats were injected with saline

(0), a half maximally activating dose (0.1 U/100 g), or a
supramaximally activting dose (5 U/rat) of insulin via tail vein.

Five

min after injection, receptors were isolated in their in vivo
phosphorylated state and kinase activity measured as described in the
legends to Figs. 4 and 5.

A.

Kinase activity towards histone H2b.

Phosphate incorporated into the 8 subunit of the insulin receptor.
Values are means + SE for 3-5 rats/group.

*p < 0.05 vs control.

B.
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CHAPTER III
KINETICS OF THE HEPATIC INSULIN RECEPTOR TYROSINE KINASE:

EFFECTS OF SUBSTRATE INHIBITION AND DIABETES
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INTRODUCTION
Insulin resistance is associated with uncontrolled insulinopenic
diabetes in humans (58,155,173,203) and in experimental models of
insulinopenia (155).

Diminished in vivo glucose disposal (58),

decreased glucose transport (27,133,277,278,307) and decreased activities of insulin sensitive intracellular enzymes (1,2,9,18) are observed
in isolated skeletal muscle (9,277,278), hepatocytes (2,181) and
adipose tissue (272) despite normal to increased insulin binding.
Insulin binding to the a subunits of the insulin receptor initiates a
cascade of autophosphorylation on tyrosine residues of the

a

subunits.

Progression of the cascade to critical sites results in activation of
the insulin receptor's exogenous tyrosine-specific kinase.

The

necessity of insulin receptor autophosphorylation and exogenous kinase
activity for insulin's coupling to its cellular effects has been established by several investigators with the use of specific antibodies
against, or by site directed mutagenesis of the
insulin stimulation of metabolic events

a

subunit which block

(Reviewed in 225).

Our laboratory and others have shown that autophosphorylation
and/or activation of the insulin receptor tyrosine kinase isolated from
skeletal muscle (30) and liver (85,123,195) of rats rendered diabetic
with streptozotocin (STZ) , is impaired after insulin binding in vitro
or in vivo.

In liver (123) the defect correlated with the severity of
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diabetes and in muscle (30) and liver (195) it could be reversed with
chronic insulin replacement.

These studies suggested that impaired

receptor activation may contribute to the insulin resistance observed
in uncontrolled IDDM.

However, others reported no effect of STZ

diabetes on autophosphorylation or exogenous kinase activity in liver
(4,85) or adipose tissue (272) measured in vitro (4,85) or in situ
(272).

The discrepancies have been ascribed to differences in the

study protocols (4,18,85) although none have been experimentally
addressed.
Several endogenous substrates for the insulin receptor tyrosine
kinase have been demonstrated in intact cells, however their identity
and/or role in the signalling process is unknown (1,14,16,97,112,
167,124,232,289).

Therefore most studies rely on the use of various

exogenous phosphoacceptors to examine insulin receptor tyrosine kinase
activity in vitro.

Many of these are excellent substrates for the

activated receptor but at levels above their Km, can also inhibit
activation of the insulin receptor kinase (23,148,156,233,248).

It is

not known whether substrate inhibition contributes to altered kinase
activities observed with receptors isolated from insulin resistant
tissues, even though the conditions used may involve inhibition by
these substrates (4,85).
The native structure of the insulin receptor is believed to be the
S-a-~-S

tetramer linked by disulfide bonds (53).

However,

a·a

dimers

have been isolated from liver membrane preparations without the use of
reducing agents (147,169).

Since

a-a

dimers generated experimentally

by reducing agents possess decreased insulin stimulated autophosphory-
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lation and exogenous kinase activity compared to intact tetramers
(20,260) differences in insulin receptor kinase activity observed
between receptors isolated from diabetic and control rats may be due to
the prevalence of dimers.
The present study was designed to address three questions:

1.)

Does substrate inhibition play a role in the differences in exogenous
kinase activity observed between receptors isolated from livers of
control and STZ-diabetic rats?

2.)

Are the effects of STZ diabetes on

insulin receptor kinase activity expressed differently towards different substrates?

3.)

Is the proportion of

a-a

insulin receptor dimers

increased in livers of rats with streptozotocin-induced diabetes?
MATERIALS AND METHODS
Materials:

Streptozotocin was a gift from Upjohn Research

Laboratories (Kalamazoo, MI).

Mono component, crystalline pork insulin

was a gift from Dr. Ronald Chance and monoiodinated Al4 125I-insulin
from Dr. B. H. Frank and Dr. R. diMarchi, Lilly Research Laboratories
(Indianapolis, IN).

Polyclonal antiinsulin receptor antibody P5 was a

gift from Dr. Ora M. Rosen, Memorial Sloan-Kettering Cancer Center (New
York, NY).
NJ)

Histone H2b was from Worthington Biochemicals (Freehold,

Protein-A-bearing Staphylococcus aureus (Pansorbin) from Calbio-

chem-Behring (Los Angeles, CA) was treated before use with 2-mercaptoethanol.

Wheat germ agglutinin (WGA) was from Vector Laboratories

(Burlingame, CA) .. Aprotinin was from FBA Pharmaceuticals (New York,
NY).

[y_32 p ]ATP was prepared from [32P]orthophosphate (lCN

t

Cambridge,

MA) in Gammaprep vials (Promega Biotec, Madison, WI) as described by
the manufacturer.

Electrophoresis apparatus was from LKB Instruments
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(Houston, TX).
berg, FRG).

Reagents for electrophoresis were from Serva (Heidel-

X-Omat AR Autoradiography film was from Eastman Kodak

(Rochester, NY).
Amicon (Danvers
NJ).

t

Centricon 10 and 30 miniconcentrators were from
MA).

Sepbadex G-50 was from Pharmacia (Piscataway,

Bio-Gel A was from Bio-Rad (Richmond, CA).

All other reagents

were from Sigma Chemical (St. Louis, MO).
Animals:

Male wistar BR rats (Charles River Laboratories,

Wilmington, MA) weighing 100-180 g were allowed access to standard
rodent chow and water ad libitum.

Diabetes was induced with streptozo-

tocin in citrate buffer, pH 4.5, by a single intravenous dose of
100-120 mg/kg body wt to overnight fasted rats.
weeks following induction of diabetes.

Rats were studied 2-3

Only diabetic rats with 4+

glycosuria, measured by Tes Tape (Eli Lilly) and minimal or no weight
gain were used.

Livers were extracted from animals for isolation of

insulin receptors after anesthesia with Methoxyfluorane (Metofane,
Pitman-Moore, Washington Crossing, NJ).
Insulin receptor purification:

Livers (-1 g) from anesthetized

control or diabetic rats were rapidly frozen in liquid nitrogen and
insulin receptors were solubilized and partially purified by WGA
affinity chromatography as described previously (18), with minor
modifications.

Tissues were powdered and homogenized at 4°C in 50 mM

N~2-hydroxyethylpiperazine-N'-2-ethanesulfonic

acid (HEPES), pH 7.4,

1.5% Triton X-100, 1 trypsin inhibitory unit/ml of aprotinin, 5 roM
EDTA, 1.5 mg/ml bacitracin, 1 mg/ml benzoyl arginine ethyl ester
(BAEE), 1 mg/ml tosyl arginine methyl ester (TAME), 1 mg/ml
benzamidine, 3 ug/ml leupeptin, and 2 roM phenylmethylsulfonyl fluoride
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(PMSF).

Following centrifugation at 4°C, 10,000 g for 10 min, the

supernatant was centrifuged at 150,000 g for 90 min at 4°C.

The

supernatant was then cycled 3 times over a YGA column (-2 ml)
preequi1brated with 50 roM HEPES, pH 7.4, 0.1% Triton X-100 at 25°C.
After washing the column with 100 m1 of the same buffer, glycoproteins
were eluted with this buffer supplemented with 0.3 M Nacetylg1ucoasamine.

YGA eluates were then aliquoted and stored frozen

at -70°C until use.
Insulin binding:

Equilibrium insulin binding with A-l4 125I-Insu-

lin and unlabelled insulin, followed by PEG precepitation of insulin
receptor complexes was performed as described previously (30).

Equal

insulin binding activities in YGA eluates from control and diabetic
liver for use in kinase assays was determined by ratios of binding at
several insulin concentrations as described previously and at 2 WGA
eluate concentrations.
Exogenous substrate kinase assays:
used:

Two exogenous substrates were

histone H2b or the synthetic polymer, poly (Glu-Tyr) (4:1).

For

assays with histone H2b, equal insulin binding activities of control
and diabetic liver (-10 - 50 fmoles) were incubated without or with
10- 7 M insulin in buffer containing 50 roM HEPES, pH 7.4, 0.1% Triton X100, 0.05% bovine serum albumin (BSA) and 5 roM MnCl2 at 4°C for 16 h.
To examine the effects of substrate inhibition samples were then
incubated without or with increasing concentrations of H2b (0.2 - 1000
ug/ml) at 25 0 C for 10 min.

Phosphorylation was then initiated by the

addition of y_[32 p ]ATP (25 uCi/nmo1, concentrations indicated in figure
legends) and 100 uM Na3V04, and reactions were allowed to proceed for 4

81

min at 25°C.

In some experiments phosphorylation was initiated before

the addition of R2b with 100 uM.

01:

25 u.M." \. 32~\~i."i? an.d. con.t:.i.n.ue.d

£01:

4.

min at 25°C or 30 min. at 4°C, respectively when H2b (40 - 1000 ug/ml)
was added.

Reactions were then allowed to proceed for an additional 4

min at 25°C or 20 min. at 4°C respectively.

All reactions involving

H2b were stopped by the addition of four times concentrated Laemmlits
sample buffer supplemented with 5% 2-mercaptoethanol (final concentration), followed by boiling for 3 min, with subsequent separation of
proteins by sodium dodecy1 sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) using a 5-19% polyacrylamide gradient.

To hydrolyze serine

and threonine phosphates and enrich for phosphotyrosine, stained gels
were digested with 1 N NaOH at 55°C for 1 h.

Histone H2b and the

a-

subunit of the insulin receptor were localized by autoradiography,
bands were excised and digested in 30% H202 and 32p quantified by
scintillation spectrophotometry.

An area of the gel, free of phos-

phoproteins, equivalent, to the size of the excised bands was excised,
digested, counted and subtracted as background.
For assays with poly (Glu-Tyr) 4:1, equal insulin binding activities (-SO fmoles) of WGA eluates from control and diabetic livers were
incubated without or with insulin as described in the figure legends in
buffer containing SO roM HEPES, pH 7.4, 2 roM MnCI2, 10 roM MgCl2' and
0.05% BSA at 4°C for 16 hr.

Substrate was then added in the concentra-

tions indicated in the figure legends.

After 10 min at 25°C, phos-

phorylation was initiated by addition of 25 uM [y.32 p ]ATP (10 uCi/nmol)
and 100 uM Na3V04, and was stopped after 4 min at 25°C by the addition
of 50 roM unlabelled ATP.

Samples without substrate were assayed in
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parallel for use as background.

Samples were then spotted onto Whatman

3MM filter paper, precipitated, washed and counted as described
previously (18).
All kinetic assays were performed on one pair of control and
diabetic receptor preparations in each experiment.

All kinase assays

involving exogenously added substrates were performed under conditions
which were determined to be linear with regards to time and WGA eluate
concentration from diabetic and control liver.

Kinase assays were

performed under conditions in which ATPase activity was determined
previously to be undetectable.

ATPase activity was determined by

separation of Pi and ATP before and after kinase assays by high
pressure liquid chromatography as described previously (30).
Autophosphorylation:

Autophosphorylation reactions were carried

out under identical conditions as described for exogenous kinase assays
involving histone H2b, with the exception that in some assays, reactions did not include H2b.
Immunoprecipitation:

Immunoprecipitation of insulin receptors

bound to l25I-insulin by anti-PS (1:100 antibody dilution) was carried
out with equal insulin binding activities of WGA eluates from diabetic
and control liver as described previously (32) except that NaCl
concentration was 150 roM and PMSF was not included in the buffer.
Preparation and isolation of dimers:

Dimers were prepared as

described previously by Sweet et a1. (259) with minor modifications.
WGA eluates from control liver were concentrated with Centricon 30
miniconcentrators to a protein concentration of 1.5 ug/m1, adjusted to
pH 8.5 with 1.0 M Tris and incubated

a~

2S o C for 25 min.

Dithio-
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threito1 (2 roM, OTT) was then added for 5 min at 25 0 C followed by
immediate separation of samples from OTT by gel filtration at 4 0 C on a
Sephadex G-50 column preequilibrated with buffer containing 50 roM Tris,
pH 7.6, 150 roM NaCl, 0.1% BSA, 0.1% Triton X-lOO and 0.02% NaN3Alternatively, YGA eluates were incubated overnight at 4 0 C with 2 roM
DTT and then separated from OTT as described above.

Samples were then

concentrated using Centricon 30 miniconcentrators and resuspended in
buffer containing 10 roM Tris, pH 7.6, 150 roM NaCl, 0.1% Triton X-lOO
and 0.02% NaN3 (column buffer) supplemented with 0.1% BSA, and
subjected to gel filtration on a Bio-Gel A 1.5 M column (2.7 cm x 60
cm) preequilibrated with column buffer supplemented with 0.1% BSA.

YGA

eluates from control and diabetic liver were also treated as described
above except without the addition of OTT.

Molecular weight standards,

Blue Dextran (Vo) , Ferritin (440K), Myosin (20SK) and Phosphorylase B
(97.4K) were run in column buffer in parallel on a column
preequilibrated with column buffer.
Detection of dimers and tetramers:

Bio-gel eluate fractions (0.4

m1) were collected and each incubated for 16 hr at 4 0 C with l25I-Insulin (10. 11 M) without or with 10. 6 M unlabeled insulin in buffer
containing 50 mM HEPES, 0.1% Triton X-lOO, 0.1% BSA, 150 mg/ml bacitracin (binding buffer); and either 10 roM NaCl (low salt), pH 7.0 or 150
roM NaCl (high salt), pH 7.6 to optimize for insulin binding by dimers

and tetramers, respectively. Following equilibrium insulin binding,
samples were analyzed by one of two methods:

In the first method,

insulin-receptor complexes were precipitated by standard PEG precipitation as described previously (30). In the second method insulin was
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crosslinked to its receptor with 2 roM dissuccinimidyl suberate (DSS) as
described previously (30).

Radioactivity in samples precipitated with

PEG was quantified in a gamma counter.

Proteins in samples crosslinked

with DSS were separated by nonreducing SDS-PAGE with a 4-10% linear
polyacrylamide gradient, after addition of 15 roM N-ethylmaleimide (NEM)
and Laemmli's sample buffer.

Labelled bands were identified by autora-

diography of stained, dried gels.

Fractions from columns with molecu-

lar weight standards were analyzed by UV absorbption at 280 nm with a
spectrophotometer.
Histone binding to ATP:

25 uK ATP, in the absence or presence of

5 roM MnC12, was incubated without or with increasing concentrations of
histone H2b (.008 - 1.0 mg/ml) in buffer containing 50 mM Hepes, 0.1%
Triton X-IOO, pH 7.4 for 4 min at 25 0 C.

After separation of free and

bound ATP with Centricon 10 miniconcentrators at 4 o C, free ATP
concentration was measured by UV absorption at 259 nm with a spectrophotometer.
Kinetic analysis:

Kinetic constants for reactions involving

substrate inhibition were determined by non-linear least squares fit of
the data to the equation V - (Vmax*[S])/(Km + [S] + [S]2/Ki) as
described by Cleland (41).

Kinetic constants for uninhibited reactions

were obtained either by fitting to the non-linear form of the
Michaelis-Menten equation by least squares analysis as described (67)
or by conversion of the data to double-reciprocal plots and analysis by
linear regression.

When analyzed both ways, constants obtained by

non-linear and linear regression were similar.

Kinetic constants

obtained from data in the absence of insulin are not shown as the low
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activity in the absence of insulin precluded accurate estimates of the
constants.
Statistical analysis:

Statistical analyses were performed by the

Students t-test or paired Students t-test when control and diabetic
derived receptor preparations were assayed in pairs.

Analysis of

variance (Peritz' F-test) was performed on data involving an insulin
dose response.
RESULTS
Kinetics of insulin receptor kinase activity towards H2b:

To

examine the effect of substrate inhibition on insulin receptor kinase
activity towards H2b, histone H2b was incubated with insulin receptors
without or with prior exposure to insulin and before addition of ATP.
The resulting histone dose response curve was biphasic (Fig la) with
receptors isolated from both control and diabetic rats in the absence
and presence of insulin.

Inhibition of insulin-stimulated kinase

activity occurred at much lower levels of H2b than inhibition of basal
kinase activity.

In the presence of insulin and low concentrations of

H2b, (0.2 - 0.5 ug/m1) the tyrosine kinase activity towards this
substrate of receptors isolated from livers of diabetic rats was either
not significantly different or significantly increased when compared to
controls by paired t-test.

However, in the presence of insulin and

higher concentrations of H2b, (.001 - 1 mg/ml) tyrosine kinase
activity of diabetic-derived receptors was significantly lower than
that of controls.

Lineweaver-Burke plots of the insulin stimulated

data were curvilinear indicative of substrate inhibition (fig Ib).
These data suggested that one or more kinetic constants (Km,Ki or Vmax)
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was altered with receptors isolated from diabetic rats compared to
controls.

Table 1 shows the kinetic constants obtained from curves in

the presence of insulin.

The Kmapp and Vmaxapp for H2b of ,diabetic-

derived receptors was significantly lower than that of controls.

The

Kiapp for inhibition of exogenous kinase activity was not significantly
different between the two groups.
Inhibition of autophosphorylation by H2b:

To assess the effects

of H2b addition prior to receptor activation on autophosphorylation,
radioactivity incorporated into the

a subunit

of the insulin receptor

was determined in the experiments described in fig lao

Histone inhibi-

ted autophosphorylation of receptors isolated from diabetic and
control rats in a dose-dependent manner (fig lc).

Insulin stimulated

autophosphorylation was significantly lower in receptors isolated from
diabetic rats compared to controls at all concentrations of histone in
this experiment (fig la), whereas there was no apparent difference
between diabetic- and control- derived receptors in the concentration
of histone eliciting half maximal inhibition (Ki app ) of insulin
stimulated autophosphorylation (-0.4 mg/ml).

This concentration was

-10 fold greater than the Ki for inhibition of exogenous kinase
activity, indicating that inhibition of exogenous kinase activity is
not a direct result of inhibition of total autophosphorylation.
Effect of histone on free ATP:

To test the possibility that

inhibition in these reactions could be due to binding of ATP by high
levels of H2b, free ATP concentrations were measured in a separate
reaction after addition of increasing concentrations of histone H2b to
25 tiM ATP or Mn 2+-ATP (Fig 2).

In the absence of Mn 2+, an H2b concen-
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tration-dependent diminution of free ATP was observed above 0.2 mg/ml
H2b.

However, in the presence of 5 mM Mn 2+, no effect of H2b on free

ATP was observed.

These results indicate that the inhibition by H2b is

not due to a reduction in free ATP since Mn 2+ (5 roM) was included in
all kinase assays.
ATP kinetics:

The following experiment was performed to determine

the mechanism of insulin receptor tyrosine kinase inhibition by H2b and
to assess whether differences in the inhibition pattern of receptors
from control and diabetic rats was due to altered ATP kinetics.
Receptors isolated from livers of control and diabetic rats were
incubated with insulin, followed by a concentration of histone which
did not alter free ATP concentration under either of the conditions
tested above (0.008 mg/ml), or a concentration of histone which
markedly decreased free ATP concentration (0.4 mg/ml) in the absence of
Mn2+; prior to addition of increasing concentrations of ATP (5 - 150
uM)

(Fig 3a).

Maximal velocity of histone phosphorylation was

achieved in all reactions at -25 uK ATP.

The inhibition of kinase

activity by high levels of H2b (0.4 mg/m1) was not overcome by increasing ATP concentrations up to 150 uK.

Differences between the

velocities of diabetic- and control- derived insulin receptor kinase
activities towards H2b persisted at all ATP concentrations.
Lineweaver-Burke plots of the data are shown in fig 3b.

Kinetic

constants obtained after analyzing the data are shown in Table 2.
In the presence of 0.4 mg/ml H2b, the Kmapp for ATP of control-derived
receptors was significantly lower than that observed in the presence of
.008 mg/ml H2b (9.44 + 1.69 uK) when analyzed by paired t-test (n-6
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pairs, p < 0.05).

High concentrations of H2b also decreased the Kmapp

of the diabetic receptor for ATP by the same magnitude (- 2 fold)
although this difference did not reach statistical significance.

In

both groups, Vmax app was significantly lower (-2 fold) in the presence
of 0.4 mg/ml H2b than with 0.008 mg/ml (p < 0.05 by paired t-test, n-6
pairs).

These data rule out competetive binding or sequestration of

ATP by H2b.

A decrease in both Vmax and KID for ATP by H2b is

indicative of a mixed type inhibition.
The Vmaxapp for ATP of diabetic-derived receptors at 0.008 mg/ml
and at 0.4 mg/ml H2b was significantly lower (-2 fold) than that of
receptors derived from controls (p <0.05 by paired t-test, n-6 pairs).
The Kmapp for ATP of receptors isolated from diabetic rats was not
significantly different than that of controls at either H2b
concentration tested.

These data suggest that differences in the

inhibition pattern between control and diabetic derived receptors.are
not due to differences in available ATP levels.
Kinetics of H2b kinase activity after activation of receptors
with insulin and ATP:

In an attempt to prevent inhibition of auto-

phosphorylation and exogenous kinase activity, receptors isolated from
control and diabetic rats were incubated with a maximally activating
concentration of insulin (10- 7 M) and ATP (100 uM) prior to H2b
addition (Fig 4a).
4b.

Resulting Lineweaver-Burke Plots are shown in fig

The parabolic nature of these plots could indicate that there is

still some inhibition by H2b or alternatively, positive cooperativity
in substrate binding (napp

=

2 by Hill plot, not shown) (243).

Kinetic

constants obtained by analysis of these data by the same method used
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for the data presented in fig 1 are shown in Table 3.

The Km, Ki and

Vmax were not significantly different between the two groups when
analyzed this way (inhibition by H2b) , or after linear

~egression

analysis of double reciprocal plots of velocity vs [H2b]2 (positive
cooperativity (243) nor after fitting the data to the non-linear form
of the Michaelis-Menten equation (regular Michaelis-Henten kinetics).
The lack of significant differences in Km or Vmax towards H2b between
control- and diabetic- derived receptors may be due to the relatively
large standard error of the measurements in this assay.

Therefore, WGA

eluates derived from diabetic and control rats were also preactivated
with 25 uM ATP and exogenous kinase activity assayed at 4°C.

Under the

latter conditions, the Km for H2b was increased compared to the former
conditions (compare table 4 with table 3) allowing the use of higher
receptor concentrations; and coupled with the higher specific activities obtainable at 25 uM ATP vs 100 uM, increased total counts were
obtained.

Under these conditions, no apparent inhibition of exogenous

kinase activity was observed at high levels of H2b (fig Sa).

When data

were fit to the non-linear form of the Michaelis Menten equation no
significant difference in the

Km

for H2b was found between control and

diabetic derived receptors whereas the Vmax was significantly lower in
the diabetic-derived preparation (Table 4).

However, this decrease in

Vmax was of much smaller magnitude (-25%), compared to the decrease in
Vmax when H2b was added to assays prior to autophosphorylation (-70%,
see table 1).
Autophosphorylation in prephosphorylated assays:

When histone was

added after ATP, we did not observe inhibition of control- or diabetic·
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derived insulin receptor autophosphorylation (figs 4c and 5b).

Total

phosphate incorporated into the 8 subunit of diabetic and controlderived insulin receptors was not significantly different in this
experiment.

In numerous experiments (data not shown) we observed

considerable variability in autophosphorylation of diabetic insulin
receptors isolated from liver (-50-100% of controls).

The reasons for

this are unclear but may be due to variability in phosphorylation of
different tyrosine residues.

Since this set of experiments was

performed on a different population of control and diabetic receptors
than those described in fig 1 (where autophosphorylation was decreased
in diabetics) an experiment was carried out to ensure that the
differences in exogenous kinase activities of prephosphorylated
receptors vs non-prephosphorylated receptor exogenous kinase activity
(fig 4 and 5 vs fig 1) did not reflect differences in the autophosphorylation ability between different receptor popUlations.

In this

experiment, receptors which had been used to obtain the data in figure
5 were incubated without or with 10- 7 M insulin, in the absence or
presence of .0003 or 0.4 mg/ml H2b and allowed to phosphorylate as
described in the legend to figure 1.

Results from this experiment

showed no significant difference in autophosphorylation between control
and diabetic receptors without or with H2b even though
autophosphorylation was inhibited (-50%) in both groups in the presence
of 0.4 mg/ml H2b (data not shown).

Furthermore, exogenous kinase

activity of diabetic-derived receptors was -2 fold greater than that of
controls in the presence of .0003 mg/ml H2b and -2 fold less than that
of controls in the presence of 0.4 mg/ml H2b (p < 0.05,

n~6).
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Therefore the same trends in exogenous kinase activity as described in
fig 1 were observed in the absence of significant differences in
autophosphory1ation between diabetic- and control- derived receptors.
Kinase activity towards poly glu-tyr (4:1):

Since discrepancies

have been reported in the effect of STZ-diabetes on kinase activity
towards Poly-Glu Tyr (4:1), exogenous kinase activity towards this
substrate was measured with receptors isolated from livers of control
and diabetic rats after incubation without or with increasing
concentrations of insulin.

A saturating concentration of substrate was

then added before activation of insulin receptors with ATP.

This

concentration of substrate (2 mg/m1) results in marked inhibition of
autophosphorylation without apparent inhibition of exogenous kinase
activity (Morrison and Pessin (186) and data not shown),

Figure 6

shows the insulin dose-dependent increase in kinase activity towards
this substrate in receptors from controls and diabetics.

No

significant difference in kinase activity between the two groups was
detected at any insulin concentration.
Kinetics of kinase activity towards poly glu·tyr (4:1):

Experi-

mental truncation of the insulin receptor has been shown to have no
effect on autophosphorylation or kinase activity towards saturating
levels of poly glu tyr (4:1), but markedly decreased exogenous kinase
activity towards low concentrations of this substrate, indicating that
at least one type of structural alteration may alter the affinity of
the receptor for poly glu tyr (4:1).

To assess whether the affinity

for this substrate and/or substrate inhibition of receptor activation
by this substrate is altered in diabetes, insulin receptors from

92

control or diabetic liver were incubated with increasing concentrations
of poly glu-tyr after incubation with insulin and before addition of

ATP.

This treatment resulted in biphasic dose-response curves (Fig 7)

similar to' that seen with histone H2b.

However, unlike the reactions

with H2b, there was no significant difference in the kinase activity
between control and diabetic derived receptors at any substrate
concentration.

Kinetic constants derived from these data (Table 5)

indicate no significant difference in the apparent KID, Vmax or the Ki
of exogenous kinase activity for poly glu-tyr (4:1) between control and
diabetic-derived receptors.
Immunoprecipitation with anti-insulin receptor antibody:

The

substrate selective effects of diabetes indicated that the substrate
binding domain of the insulin receptor may be altered by diabetes.
Typically, the substrate binding sites of tyrosine kinases are located
at the carboxyl terminus (296).
the

a

In addition the carboxyl terminus of

subunit is more susceptible to proteolytic degradation than other

portions of the molecule (140,229).

Proteolysis mayor may not affect

exogenous kinase activity towards various substrates (244,290).

We

therefore examined the precipitability of insulin receptors from
control and diabetic liver with a polyc1onal anti-insulin receptor
antibody (anti-PS) raised against the derived peptide sequence (amino
acid residues 1328 to 1343) near the carboxyl terminus of the
of the human placental insulin receptor (108).

a

subunit

The percentage of total

binding precipitated by PS was similar to values obtained previously in
our laboratory using the same antibody dilution (32).
difference in the precibitability of

to~al

No significant

insulin binding by this
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antibody was observed between WGA eluates isolated from diabetic and
control rats (67.9 ± 2.6% vs

73.5 ± 2.62%, respectively, n-3).

Therefore, this immunochemical technique did not reveal differences in
a portion of the molecule potentially involved in substrate binding.
The data indicate that apparent differences in kinase activity observed
between receptors isolated from diabetics and controls probably do not
reflect preferential proteolytic degradation of the carboxyl terminus
of the receptor in diabetic liver.
Assessment of insulin receptor dimers and tetramers in WGA
preparations.

Equilibrium 125I-Insulin binding carried out at pH 7.6

in high salt buffer revealed that control receptors treated with DTT
eluted at a M.W. of -200 kD (Fig 8).

Total binding was decreased -50%

under these buffer conditions compared to control receptors which were
not treated with OTT. (data not shown).

No significant detectable

binding was observed in fractions which eluted at a M.W. of -400 Kd
after DTT treatment, indicating complete conversion of tetramers to
dimers.

Binding from untreated receptors isolated from control or

diabetic liver eluted at a M.W. of -400 Kd.

No binding was detected in

fractions eluting at a M.W. of -200 Kd from any preparations not
treated with DTT (fig 8).

Total binding performed in pH 7.0, low salt

binding buffer was decreased compared to binding in pH 7.6

t

high salt

binding buffer in WGA eluates from control and diabetic rats and all
binding activity from native (not exposed to DTT) preparations
assessed under these conditions eluted from the gel filtration column
at a M.W. of -400 Kd (data not shown).

Thus, dimers were not detected

under conditions optimized for tetramers or dimers.

From the data in
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Fig 9 we estimate that we would have detected the presence of dimers in
the native preparations had they comprised at least 5% of the total
insulin receptor population.

These data indicate that

dimers were not

present in insulin receptor preparations from control or diabetic liver
in this study.

This was confirmed by crosslinking 125I-insulin to the

insulin receptor followed by nonreducing SDS-PAGE. (Fig. 9).

Intact

tetramers were identified in native control and diabetic receptor
preparations (lanes A and E) in fractions eluting from the gel
filtration column at a M.W. of -400 kD.

No proteins migrating at a

M.W. of -200 kD were specifically labelled in fractions eluting from
gel filtration columns at a M.W. of -200 kD (lanes C,D,G and H) or -400

kD, (lanes A,B,E and F) confirming the absence of dimers in the native
control and diabetic WGA peparations.

A specifically labelled band

migrating at an apparent M.W. of -200 kD (lane L) was detected in
fractions eluting from the gel filtration column at a M.W. of -200 kD
indicating the presence of dimers in DTT-treated WGA eluates.

This

band was not present in fractions eluting from the gel filtration
column at a M.W. of -400 kD (lane J).

DISCUSSION
Our results agree with a previous study by Okamato et al. (195) in
which insulin stimulated tyrosine kinase activity towards histone H2b
(.1 mg/ml) was decreased -50% in receptors isolated from livers of
severely insulinopenic rats compared to controls.

In the current

study, kinetic analysis further reveals that the KID and Vmax for H2b of
insulin receptor kinase activity purified from diabetic rat liver is
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markedly decreased compared to controls when insulin bound receptors
were exposed to H2b before, but not when exposed to the substrate after
maximal autophosphorylation.

When receptors were activated with

insulin and ATP prior to addition of H2b, the KID for H2b was unaltered
and the maximal velocity was only slightly decreased (-25%) with receptors from diabetics when compared to controls.

These data suggest that

a structural alteration in the diabetic receptor manifested in the
unactivated state render kinase activation more susceptible to inhibition by H2b.

The Km, Vmax and Ki values obtained by kinetic analysis

were at best apparent, not intrinsic values, as data were fitted to an
equation which is dependent only on the varied substrate and may be
used for all substrate inhibitions resulting in linear (i.e. total)
inhibition (41,242); thus it does not account for all substrates and
interaction factors in this system.

The substrate inhibition appeared

to be complete since reaction rates were driven essentially to zero
(i.e. to levels observed in the absence of insulin) by high levels of
H2b and data did not fit partial (hyperbolic) inhibition models
(42,242).

The linear substrate inhibition equation was used only as a

simplified model to show quantitative differences between control- and
diabetic- derived insulin receptor kinase activity.

Since the kinase

is activated by autophosphorylation during the course of the nonprephosphorylated reactions and because there is potential for
interactions between substrate binding sites, a more extensive
experimental approach would be required for more accurate kinetic
analysis and was beyond the scope of these studies.

If one compares

the kinetics of prephosphorylated vs non-prephosphorylated receptors
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using this equation, it appears that when H2b is present during
activation it decreases both the apparent Km and Vmax for H2b,
consistent with a mixed type inhibition mechanism.

While these effects

are apparent in both control- and diabetic-derived receptors, the
effect is much greater in the latter.

Our data suggest more than one

binding site for H2b per insulin receptor molecule.

Since there are 2

S subunits per receptor which could function independently as a
tyrosine kinase, it is possible that binding of histone to one of the
subunits inhibits activation of that subunit but increases the affinity
of the second substrate site on the other 8 subunit.

If the second

substrate binds before activation by ATP, complete inhibition occurs.
However, if the second 8 subunit is activated by ATP prior to binding
of the second substrate, increased affinity towards the second
substrate results in increased activity of the uninhibited 8 subunit
towards H2b at low H2b concentrations.

Thus, occupancy by histone on

one 8 subunit may change the kinetics of the other.

Therefore, H2b may

act as both an activator and an inhibitor of exogenous tyrosine kinase
activity.

This model could also account for the apparent positive

cooperative effects of H2b we observed with preactivated receptors.
The Km for H2b in our assays was considerably lower (-.002 mg/ml)
than reported by others (.1 - 1 mg/ml) for this substrate
(142,156,186,303).

Differences in apparent Km values between data are

likely due to: the use of receptors isolated from different tissues
(156,186); WGA purified vs affinity purified receptors (156,186);
measurement of kinase activity in a solubilized system vs immobilized
on insu1in-agarose (303) and measurement at 25 0 C vs 4°C (142).

We
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observed higher Km values for H2b when soluble receptors were assayed
at 4°C (-.04 mg/ml) and after receptors were adsorbed to
insulin-agarose beads (data not shown).

When we attempted to do

kinetic analysis of receptors adsorbed to insulin agarose beads,
interactions of substrates with the agarose matrix were observed
resulting in considerable depletion of the substrate.
We did not consistently observe significant differences in
autophosphorylation of insulin receptors from diabetic and control rats
under conditions utilized in these assays.

Furthermore, we did not

detect differences in the ability of H2b to inhibit diabetic and
control derived receptor autophosphorylation.

While it is generally

believed that autophosphorylation of the insulin receptor is a prerequisite for activation of exogenous kinase activity, numerous
investigators have shown that total autophosphorylation does not always
correlate well with exogenous kinase activity (227 269,290,303).
f

White

et a1. (290) recently showed that when progression of the
autophosphorylation cascade to the 3rd critical site was blocked,
phosphorylation of the first two sites actually increased.

Similarly,

Obermaier-Kusser et a1. (189) reported that decreases in exogenous
kinase activity of insulin receptors isolated from muscle of patients
with non-insulin dependent diabetes mellitus (NIDDM) correlated highly
with the extent of phosphorylation of the third critical site but
poorly with phosphorylation of the first two sites (189).

In addition,

decreased exogenous kinase activity without concomittant decreases in
autophosphorylation have been reported with receptors isolated from
livers of rats fed low carbohydrate die.ts (79) and in skeletal muscle
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of patients with NIDDM (35).

Thus, conclusions regarding the

relationship of autophosphorylation to exogenous kinase activity cannot
be predicated solely on measurement of total autophosphorylation.
Shoelson et a1. (248) recently proposed that substrate inhibition by
synthetic substrates prevents the phosphorylation of critical sites in
the tyr 1150 domain of the insulin receptor.

Inhibition by H2b in our

assay may be due to preferential inhibition of these sites, or to
selective alteration of the rates of phosphorylation of critical sites
in diabetic preparations without affecting total receptor autophosphorylation.
No significant differences between control- and diabetic- derived
insulin receptor kinase activity towards poly glu-tyr (4:1) was
detected at any substrate concentration or after exposure to several
insulin concentrations.

Similarly Truglia et al. (272) did not observe

effects of STZ diabetes on kinase activity towards this substrate·with
insulin receptors isolated from adipocytes after insulin stimulation in
vitro or in situ.

However, Gherzi et al. (85) reported an -50%

decrease in exogenous kinase activity of receptors isolated from livers
of STZ-diabetic rats compared to controls towards this substrate.
reasons for these discrepancies are still unclear.
concentrations utilized in these studies differ.

The

The Mn 2+ and Mg2+
In our hands t kinase

activity towards poly glu-tyr (4:1) is highly dependent on both the
Mn 2+ and Mg2+ concentrations in the assay (data not shown).

Further-

more, we found that differences in Mn 2+ and Mg2+ concentrations
required for optimal activity towards this substrate vary depending on
the average M.W. of the synthetic peptide.

Thus, the absolute tertiary
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structure obtained by poly glu-tyr (4:1) may depend on the Mn 2+ and
Mg2+ concentration and possibly other conditions of the assay.
Examination of tyrosine kinase activity towards poly

gl~-tyr

(4:1) with

several Mn 2+/Mg 2+ concentrations (1 mM/10 roM, 5 mM/10 roM, 10 roM/10 roM)
or with 5 mM Mn 2+ in the absence of Mg did not reveal significant
differences between diabetic and control receptor kinase activity at
several poly glu-tyr (4:1) concentrations (data not shown).

Therefore,

under conditions optimized for kinase activity towards poly-glu-tyr or
under conditions identical to those used for the H2b assay, we could
not detect differences in kinase activity between the two types of
receptors with poly glu-tyr (4:1).
Several possible mechanisms may explain why the altered tyrosine
kinase activity of diabetic receptors is selective for substrates.
Peptide substrates do not have as rigid a tertiary conformation as
globular proteins and the activities of enzymes towards synthetic
substrates do not always mimic those of proteins whose sequences they
are derived from (38,287).

Therefore, the poly giu tyr (4:1) substrate

may fit an altered binding site more readily than a protein with
relatively more conformational constraints such as histone H2b.
Deletion of portions of the insulin receptor

S subunit may

abolish, decrease or have no effect on insulin receptor tyrosine kinase
activty depending on the extent of deletion (140,244).

Deletion

mutagenesis of the carboxyl terminus of the insulin receptor did not
affect in vitro kinase activity towards poly glu-tyr (4:1) but may have
affected recognition of appropriate intracellular substrates (163,175).
Conceivably, this type of deletion could impair kinase activity towards
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one substrate and not another if deletion occurs at sites critical for
the binding of only certain substrates.

Proteolysis of the placental

insulin receptor, presumably by an endogenously copurified protease
(140) or of the liver insulin receptor by a membrane splitting
proteinase (244) resulted in 88 kDa S subunits with decreased tyrosine
kinase activity towards the synthetic substrate thr-12-lys or
apparently decreased afffinity but normal maximal velocity towards poly
glu-tyr (4:1), respectively.

Neither of the two clipped

B

subunits

were recognized by antibodies directed against residues 1327-1343 (the
PS domain) of the insulin receptor.

Since we did not detect differ-

ences in the precipitability of diabetic or control receptors with an
antibody raised against this domain, the substrate selective effects of
diabetes were probably not due to truncation of the receptor at the
carboxyl terminus.
The apparent effects of H2b could be due to H2b limiting the
availiability of essential activators in the in vitro assay such as ATP
(156).

We found that high concentrations of H2b (> 0.2 mg/ml)

decreased free ATP concentrations in the absence, but not in the
presence of saturating Mn 2+ concentrations.

It is unlikely that the

inhibitory effects we observed with increasing concentrations of H2b
are due to depletion of ATP since: a.) saturating Mn 2+ was present in
all assays, b.) we observed significant inhibition at levels of H2b
(.008 - .04 mg/ml) which did not deplete ATP in the absence of Mn 2+,
and

c.) inhibition by H2b could not be overcome by increasing ATP.

Our results therefore are in agreement with Shoelson et ale (248) which
indicated that inhibition of tyrosine kinases by some substrates is not
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due to competition with ATP binding. Furthermore it is unlikely that
the effects of diabetes were due to altered ATP binding or altered
available ATP since the Km for ATP was not significantly different
between diabetic- and control- derived receptors and because the
effects of diabetes were not overcome by increasing ATP levels.
Okamoto et a1. (195) showed that decreases in insulin receptor
kinase activity from liver towards H2b correlated with severity of
diabetes.

To control for severity of diabetes

t

different kinetic

assays were either performed with the same receptor preparations, or
when this was not

possible~

effects with one assay (with one or two

concentrations of substrate) were always pre-established before performing the other assays on any given pair of diabetic and control
receptor preparations.
The detection of insulin receptor dimers in isolated liver plasma
membranes by Koch et al. (147) and Massague et ale (170) indicated that
the native receptor may exist in different association states.
receptor

a-a

Insulin

dimers were not detected in our preparations with the PEG

precipitation or cross1inking methods.

Therefore differences observed

between diabetic- and control- derived receptor kinase activities in
the present study were not due to the existence of dimers.

The lack

of dimers in our preparations could reflect our freezing tissues
immediately in liquid nitrogen upon isolation followed by rapid
solubilization instead of isolating membranes before purification of
receptors; thus dimers may not exist natively in rat liver. but rather
arise during isolation of receptors.
Our results with H2b are compatible with previous observations
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suggesting that STZ-diabetes causes structural alterations of the
insulin receptor (30). The present study indicates that structural
alterations in diabetes may enhance the susceptibility of activation of
the insulin receptor kinase to inhibition by putative regulatory
molecules.

Such molecules could be high levels of substrates or

inhibitors in vivo.

A second model of insulin action has been proposed

in light of evidence that some of insulin's effects may be elicited
without evidence of increased kinase activity (77,100,250,305) and that
antibodies which stimulate kinase activity mimic some but not all of
insulin's effects (211).

This model predicts that autophosphorylation

of the receptor merely serves to alter the conformation of the
receptor, resulting in non-covalent interactions of the receptor with
some other plasma membrane protein similar to systems which activate G
proteins (86,129).

Our observations suggest that the diabetic receptor

expresses altered binding to H2b and/or is less likely to change its
conformation in response to insulin in the presence of H2b; noncovalent interactions with other molecules in the plasma membrane may
be altered similarly.
In summary, our data is compatible with the hypothesis that the
metabolic alterations associated with insulinopenic diabetes cause
structural modifications of the insulin receptor and may result in
enhanced substrate inhibition of the receptor kinase.

Whether this

type of regulation is relevant to in vivo insulin action is unknown.
Since impairment of the insulin receptor tyrosin kinse activity has
been observed in streptozotocin diabetic rats after activation by
insulin in vivo, similar mechanisms may be operational in intact cells.
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The fact that the tyrosine kinase defect is expressed towards one
substrate and not another in our system suggests that the reported
discrepancies concerning the effects of diabetes on the exogenous
kinase activity of the insulin receptor may reflect in part the
selection of substrates studied.

In addition, these results emphasize

the importance of identifying and characterizing the endogenous
substrates and modifiers which interact with the receptor in vivo.
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Table 1.

Kinetic constants for H2b. Tyrosine kinase activity of
insulin receptors activated in the presence of histone H2b.

KIa

(ug/ml)

Ki
(mg/ml)

Vmax

(fmo1es Pi/
fmo1e receptor I 4 min)

Control

1.6 ± 0.36

0.021 ± 0.014

8.79 + 1.76

Diabetic

0.3 + 0.066*

0.059 + 0.047

2.97 ± 0.51*

Kinetic contstants are apparent values obtained by nonlinear least
squares analysis of the data (in the presence of insulin) presented in
figure la, according to the method of Cleland (41).
Data is presented as the mean + S.E. of constants from analysis of
inidividual curves.
*p < 0.05 compared to control by paired Student's T-test, n-6 pairs

The M.W. of

H2b~

13,800
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Table 2.

Kinetic constants for ATP in the presence of different
concentrations of histone H2b.

[H2b]
(mgjml)

Control

Diabetic

V_ax
(fmo1es Pi/
fmole receptor / 4 min)

KIa
(uM)

0.008

9.44 + 1.69

3.91 + 0.40

0.4

5.52 + 1.00

1.53

0.008
0.4

±

0.33

2.95

2.08 + 0.28*

7.21 + 1.32

0.83 + 0.17*

14.10

±

Kinetic contstants for ATP are apparent values obtained by linear least
squares analysis of double-reciprocal plots of the data presented in
figures 4a and 4b.
Data are presented as the mean + S.E. of constants obtained from
individual curves.
*p < 0.05 compared to control by paired Student's T-test, n ~ 6 pairs.
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Table 3.

Kinetic constants for H2b. Tyrosine kinase activity of
insulin receptors measured with H2b added after
autophosphorylation at 2S o C.

(mg/ml)

Ki
(mg/ml)

Control

0.0041 + 0.00103

1.528 ± 1 . 011

Diabetic

0.0062 + 0.00454

1.879

KDl

± 0.976

Vaax

(fmoles Pi/
fmole receptor I 4 min)
10.24

±

1.96

7.75 + 1.08

Kinetic contstants for H2b are apparent values obtained by nonlinear
least squares analysis of the data (in the presence of insulin)
presented in figure Sa, according to the method of Cleland (41).
Data are presented as the mean ± S.E. of constants obtained from
analysis of individual curves.
The M.W. of H2b

~

13,800
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Table 4.

Kinetic constants for H2b. Tyrosine kinase activi~ of
insulin receptors with H2b added after autophosphorylation at
4oC.

Km

Vmax

(mg/ml)

(fmoles Pi /
fmole receptor I 30 min)

Control

0.0393 + 0.0110

8.92 ± 1.47

Diabetic

0.0446

6.76

±

0.0127

±

0.94*

Kinetic contstants for H2b are apparent values obtained by least
squares analysis of the data (in the presence of insulin) presented in
figure 6, fit to the nonlinear form of the Michaelis-Menten equation as
described (67).
Values are presented as the mean ± S.E. of constants obtained by
analysis of individual curves.
The

M.W. of H2b

~

13,800

*p < 0.01 compared to control by paired Students T-test t n - 5 pairs.

lOB
Table 5.

Kinetic constants for poly glu-tyr (4:1).

Km

(mg/ml)

Ki
(mg/m1)

±

VDlax.

(fmo1es Pi/
frno1e receptor I 4 min)

Control

0.540 + 0.110

7.83

2.21

131.48 + 17.14

Diabetic

0.562 ± 0.143

9.38 + 2.95

136.87 + 18.78

Kinetic contstants for poly glu-tyr 4:1 are apparent values obtained by
nonlinear least squares analysis of the data (in the presence of
insulin) presented in figure 8, according to the method of Cleland
(41).
Data are presented as the mean + S. E.. of constants obtained by analysis
of individual curves.
M.W. of poly glu-tyr

~

45,700
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Figure 1.

Kinetics of insulin receptor tyrosine kinase activity

towards histone H2b.

Equal insulin binding activitites of YGA eluates

derived from control and diabetic liver were incubated without or with
10- 7 M insulin for 16 hr in buffer containing 50 roM Hepes, 0.1% Triton
X-100, 5 mM MnC12, 0.55% BSA, pH 7.4 at 4 o C, followed by increasing
concentrations of H2b (0.2-1000 ug/ml) for 10 min. at 2S o C.
Phosphorylati.on was ini tiated by the addi tion of 25 uM Y [32 p ] ATP and
reactions were stopped after 4 min. at 2S o C by the addition of 4X
Laemmli's sample buffer.
1 N NaOH for 1 hr. at 550C

Following SDS·PAGE and treatment of gels with
t

H2b and

a

subunit bands were localized by

autoradiography, excised and 32p counted by scintillation
spectrophotometry.

- - minus insulin, + - plus insulin.

kinase activity towards H2b.
insulin) presented in A.

A: Exogenous

B: Double-reciprocal plot of data (+

C: Insulin receptor autophosphorylation.

Each point represents the mean or mean ± S.E. of 6-11 receptor
preparations.
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Figure 2.
uM

Free ATP concentration in the presence of histone H2b.

25

ATP (ATP) or 25 uM ATP, 5 roM KnC12 (Mn-ATP) was incubated in 50 roM

Hepes, 0.1% Triton X-100, pH 7.4, without or with increasing
concentrations of histone H2b (1-1000 ug/ml) for 4 min. at 25 0 C.
After separation of free ATP from H2b by centrifugation with Centricon
10 miniconcentrators, ATP concentration was measured in the filtrate by
UV absorption at 259 nm.
determinations.

Each point represents the mean + S.E. of 3
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Figure 3.
H2b.

ATP kinetics of insulin receptors in the presence of histone

Equal insulin binding activities of WGA from control or diabetic

liver were incubated with 10- 7 M insulin in buffer containing. 50 roM
Hepes, 0.1% Triton X-IOO, 5 roM MnCl2, 0.55% BSA, pH 7.4 for 16 hr. at
4 o C, followed by incubation with either 0.008 mg/ml or 0.4 mg/ml H2b
for 10 min. at 25 0 C.

Phosphorylation was initiated by the addition of

y[32 p ]ATP (5-150 uM) and reactions were stopped and samples processed
as described in the legend to figure 1.
towards H2b.

A: Tyrosine kinase activity

B: Double-reciprocal plots of data presented in A.

Each

point represents the mean or mean + S.E. of 6 receptor preparations
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Figure 5.
at 4°C.

Kinetics of prephosphorylated receptors towards histone H2b
Equal insulin binding activities of WGA eluates derived from

control and diabetic liver were incubated without or with 10- 7 M
insulin in buffer as described in the legend to figure 1.
Phosphorylation was initiated by the addition of 25 uK Y [32 p ]ATP and
continued for 30 min at 4 0 C when H2b (0.04 - 1 mg/ml) was added.
Reactions were stopped after an additional 20 min. at 4°C and samples
were processed as described in the legend to figure 1. - - minus
insulin, +

~

plus insulin.

A: Exogenous kinase activity towards H2b.

B: Insulin receptor autophosphorylation.

Each point represents the

mean ± S.E. of 4-5 receptor preparations . .
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Figure 6.

Insulin dose-response of kinase activity towards poly glu-

tyr (4:1).

Equal insulin binding activities of WGA eluates derived

from control and diabetic liver were incubated without or with
increasing concentrations of insulin (0.1 - 100 nM) in buffer
containing 50 roM Hepes, 0.1% Triton X-100, 2 roM MnCI2' 10 mM MgCI2,
0.55% BSA for 16 hr at 4 o C.

Poly,glu-tyr (4:1) (2 mg/ml), was then

added for 10 min and phosphorylation was initiated by the addition of
25 uK Y [32 p ]ATP and reactions were stopped after 4 min at 25°C as
described in Materials and Methods.
scintillation specrophotometry.
receptor preparations.

32p waS quantified by

Data represent the mean + S.E. of 3-6
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Figure 7.

Kinetics of insulin receptor kinase activity towards poly

g1u-tyr (4:1).

Equal insulin binding activities of WGA eluates derived

from control and diabetic liver were incubated without or with 10- 7 M
insulin in buffer as described in the legend to figure 6.

Poly glu-tyr

(4:1) (0.05 - 10 mg/ml) was then added for 10 min and phosphorylation
was initiated by the addition of 25 uM Y [32pJATP.

Reactions were

stopped after 4 min at 25°C and samples were processed as described in
Materials and Methods.

minus insulin, + - plus insuln.

represents the mean + S.E. of 3 receptor preparations.

Each point
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Figure 8.

Equilibrium 125I-insu1in binding to isolated insulin

receptor dimers and tetramers.

Native and DTT-treated WGA eluates

derived from control and diabetic liver were subjected to gel
filtration as described in Materials and Methods.

Fractions were

incubated with 125I-Insulin (10- 11 M) without or with 10- 6 M unlabelled
insulin in binding buffer (pH 7.6, 150 roM NaCl) as described in
Materials and Methods.

Receptor-bound insulin was precipitated with

polyethylene glycol and samples were counted as described in Materials
and Methods.

The single and double arrows denote the elution of

Ferritin (440 K) and Myosin (205 K) molecular weight standards,
respectively from the Bio-ge1 filtration column.
representative of 3 determinations.

Data shown is a
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Figure 9.

Identification of dimers and tetramers after crosslinking

and SDS-PAGE.

Native and DTT-treated WGA eluates derived from control

and diabetic liver were subjected to gel filtration as described in
Materials and Methods.

Fractions eluting at a M.W. of -200 kD (lanes

C,D,G,H,K and L) or -400 kD (lanes A,B,E,F,I and J) were then incubated
with 125I-Insulin, without (lanes A,C,E,G,J and L) or with (lanes
B,D,F,H,I and K) 10- 6 M unlabelled insulin and proteins were separated
by non-reducing SDS-PAGE after addition of NEM as described in
Materials and Methods.

Native control- and diabetic- derived WGA

eluates are shown in lanes A-D and E-H, respectively.
control YGA eluates are shown in lanes I-L.
indicates the migration of

the~~

indicate the migration of the

as

DTT-treated

The single arrow

tetramer and the double arrows

dimer.

The gel shown is a

respresentative of 3 separate experiments.
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CHAPTER IV
STRUCTURAL DIFFERENCES BETWEEN MUSCLE AND LIVER
DERIVED INSULIN RECEPTORS

The contents of this chapter have been previously published in similar
form in J. Bio1. Chem. 261:14361-14364.
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INTRODUCTION
The insulin receptor is a heterotetramer glycopeptide composed of
two a and two S subunits which are linked by disulfide bonds (for
review see Refs 53,225,273).

Pulse-chase studies (223,237) and recent

analysis of cDNA clones (69,273) suggest that the insulin receptor is
synthesized as a Mr
glycosylated and

180,000 precursor which is subsequently

~leaved

to yield subunits of -135,000 and -95,000.

Heterogeneity in the structure of the insulin receptor has been
reported.

In brain both the a (107) and 8 (220) subunits may have

smaller Mr than those observed in adipocyte and liver, respectively_
The difference in the a subunit is apparently due to a decrease in
sialic acid content (107).

Gorden's group (177) reported that both the

a and 8 subunits of insulin'receptors isolated from a human monocyte

cell line have larger Mr than the corresponding subunits from IM-9
lymphocytes.

The 8 subunit of endothelial cells had a large Mr than

that derived from a hepatoma cell line (120).

Only in the first

instance (107) was a molecular basis for the heterogeneity suggested.
In this report we compared in rats the structure of the insulin
receptor derived from the two main in vivo target organs of insulin,
skeletal muscle, and liver.

MATERIALS AND METHODS
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Materials:

Monocomponent, crystalline pork insulin and monoiodin-

ated A14 l25I-insulin were kindly provided by Dr. Ronald Chance and Dr.
B. H. Frank, respectively, Lilly Research Laboratories" Indianapolis,

IN.

Insulin-like growth factor-I was purchased from AMGen Biologicals,

Thousand Oaks, CA.

All other reagents and chemicals were obtained as

previously reported (30).
Animals:

Male Wistar rats weighing 60-150 g were used.

Food was

withdrawn 24 h before decapitation by guillotine.
Receptor purification:

The liver and hindlimb skeletal muscles

were rapidly removed, immediately frozen in liquid nitrogen, and
processed as described previously (31).

In some experiments, addition-

al protease inhibitors (1 roM N-ethylmaleimide, 1 mg/rol bacitracin, 20
ug/ml leupeptin. 10 ug/ml pepstatin, 1 mg/ml benzamidine, and 1 mg/rol
benzoyl arginine ethyl ester) were added to the homogenization buffer.
After adsorption to wheat germ agglutinin (WGA) and washing, receptors
were eluated from the YGA column with buffer containing 50 mM HEPES. pH
7.4, 0.1% Triton X-100, and 0.3 M N-acetylglucosamine (approximately 1
ml/g original tissue weight for muscle and liver, respectively) and
used directly or further purified by immunoprecipitation.

In separate

experiments previously prepared WGA eluate from liver was dialyzed
against 50 mM HEPEs, pH 7.4, 0.1% Triton X-100, to remove N-acetylglucosame. Triton X-IOO was added to the retentate (final concentration

1%) and the receptors were added to frozen powdered muscle for reisolation.
Insulin binding:

Insulin binding was performed on the WGA eluate

as previously described (31) using A14 125I -insulin as the tracer
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(specific activity 200·250 uCi/ug, 50,000 cpm/200 u1 final volume).
Nonspecific binding (in the presence of 10 ug/ml unlabelled insulin)
was 4-6% of total binding in muscle and 0.5-2% in liver-derived
receptor preparations.
Crosslinkini:

A14 l25I-insulin was cross-linked to solubilized

insulin receptors with disuccinimidyl suberate as described (30).
Insulin binding was measured prior to cross-linking, and equal insulin
binding activities (30) from muscle- and liver-derived WGA eluates were
used.
Electrophoresis:

Under reducing conditions (5% 2-mercapto-

ethanol), electrophoresis was performed using the discontinuous system
of Laemmli (14) with a 6.5% resolving gel.

The Mr of labelled bands

was assigned by regression analysis of log molecular weight versus
relative mobility of standard proteins supplied by Sigma, e.g. myosin,
205,000; B-galactosidase, 116,000; phosphorylase b, 97,400; bovine
albumin, 66,000; egg albumin, 45,000; and pepsin, 35,000.

The assign-

ments are approximate since glycoproteins do not migrate according to
their true Mr on SDS-PAGE (15).
RESULTS AND DISCUSSION
The a subunit of the insulin receptor solubilized from muscle and
liver was identified by specific covalent coupling to A14 125I-insulin
using disuccinimidyl suberate and examination of the reaction product
by SDS-PAGE and autoradiography.

When examined under reducing condi-

tions, a protein of Mr 131,000 from WGA eluate of muscle homogenates
was labelled (Fig 1, lane G) while a protein of Mr 135,000 was labeled
in WGA eluates from liver (Fig 1, lane E).

These differences were
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observed without exception in seven separate receptor preparations.
The labeling of these two proteins was prevented by adding excess
unlabeled insulin to the radioligand prior to cross-linking (Fig 1,
lanes A and B).

The l25I-insulin cross-linked protein was identified

as the insulin receptor a subunit (as opposed to the structurally
similar IGF-I receptor a subunit (13»

by incubating the WGA eluates

with l25I-insulin and increasing concentrations of unlabeled insulin or
IGF I prior to cross-linking.

IGF-! was approximately 100 times less

potent at inhibiting l25 I -insulin crosslinking than native insulin (Fig
2A).

Since the smaller Mr of the muscle-derived insulin receptor

subunit could be caused by protease degradation during isolation,
insulin receptors from muscle and liver were isolated in the presence
of additional protease inhibitors as described under "Experimental
Procedures" but the difference between the

CL

subunits of the muscle . .

and liver-derived insulin receptors persisted (Fig 1, lanes C and D).
Furthermore, insulin receptors isolated from rat liver were dialyzed to
remove N-acetylglucosamine and added to powdered frozen muscle prior to
homogenization.

The mixture was purified by the standard procedure and

the WGA eluate was cross-linked with radiolabeled insulin; SDS-PAGE
under reducing conditions followed by autoradiography revealed an
approximately 2-fold widened band, the top of which comigrated with the
liver-derived, and the bottom with the muscle derived,

CL

subunit (Fig

1, lanes F and F').
Equilibrium binding of A14 125I-insulin to receptors in the WGA
eluate was performed to determine whether the difference in the Mr of
the a subunits resulted in functional alterations.

The yield of
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insulin receptors per gram of original tissue weight (pmol of insulin
specifically bound/g of tissue) was 7-10 times greater from liver than
from skeletal muscle.

Binding data were plotted in the form

(B/F)/(Bo/Fo) versus insulin concentration to compare the relative
affinities of the receptors for insulin directly (Fig. 2B).

The

affinity for insulin of receptors from liver and muscle was not
significantly different when data from seven separate sets of receptor
preparations were compared, although the apparent affinity of hepatic
receptors appeared slightly lower.
The above studies were carried out in collaboration with studies
by others in our laboratory. Additional studies identified differences
in the molecular weight of the 8 subunit of the insulin receptor from
muscle and liver (28).

The

e subunit

was identified by

autophosphorylation in the presence of [y.32 p ]ATP with subsequent
SDS-PAGE and autoradiography.

When the muscle-or liver-derived insulin

receptor was allowed to autophosphorylate, proteins of Mr
101,000 respectively, were labeled.

98,000 and

The labeling of these proteins was

increased in the presence of insulin in a dose-dependent manner (31),
was specifically immunoprecipitable with anti-insulin receptor
antibodies, and was thus identified as the
receptor.

e subunit

of the insulin

After purification of the receptors on insulin-agarose and

subsequent autophosphorylation the same Mr differences between muscleand liver-derived receptor
J).

B subunits were observed (Fig 1, lanes Hand

These differences persisted when the insulin receptors were

isolated in the presence of excess protease inhibitors, as described
above for the a subunit (Fig 1, lanes I. and K, and Table I).
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Subsquent studies by others in our laboratory involving glycosi·
dase digestion of individual receptor subunits before or after V-8
protease digestion revealed differences in the glycosylation of muscle
and liver-derived

a subunits

(28).

The differences between

B subunits

could be partially obliterated by treatment of receptors with
neuraminidase suggesting that differences between receptors derived
from the two tissues is due in part to increased sia1ylation of the
liver

a subunit

compared to muscle.

Treatment of insulin receptors

with neuraminidase, endoglycosidase H or the two in sequence, did not
alter the differences in the migration of muscle and liver-derived a
subunits, indicating that differences between the a subunits were not
due to differences in sialic acid content or in altered processing of
high mannose to low mannose oligosaccharides.
In experiments comparing V-8 protease digested

a subunits,

the

labeling of a phosphopeptide in the muscle-derived insulin receptor
subunit was observed which comigrated with the major phosphopeptide
derived from liver (28).

This slower migrating population in muscle

was shown to increase after the induction of streptozotocin diabetes in
the rat (30).

Subsequent studies also showed that the

insulin-stimulated tyrosine kinase activity of the liver-derived
insulin receptor was decreased (-50%) compared to muscle (32).
It is difficult to compare the Mr presented here to those reported
in the literature for insulin receptors isolated from various tissues,
due to minor differences in SDS·PAGE technique between laboratories and
the variability in the Mr assigned to phosphorylase b, the commonly
used standard which migrates near the S subunit.

In the present study,
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it was assigned 97,400 (268) but this value varies between 92,000 and
97,500 in various papers characterizing insulin receptor subunits.

It

was not until the muscle and liver-derived subunits were electrophoresed next to each other that the differences in electrophoretic
mobility became discernible.

Recent studies of insulin receptor gene

structure suggest that while there appears to be only one copy of the
insulin receptor gene, there is mRNA heterogeneity; in man, certain
mRNA species predominate in liver versus other tissues (e.g. placenta
and IM·9 lymphocytes).

A salient difference between insulin's action

in liver and a number of other tissues is a lack of insulin-stimulated
glucose transport in the former.

Morphological studies (119) highlight

differences in the distribution of insulin receptors on the cell
membrane in various tissues (e.g. liver versus adipocytes) which may
reflect in part structural heterogeneity of the receptors.

Whether or

not the structural differences described here are reflected in differences in transmembrane signalling and/or have functional implications
remains to be determined.
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Figure 1.

Autodradiogram of muscle- and liver-derived insulin receptor

B subunits.

a and

YGA eluates were prepared by the standard procedure

(lanes E, F, F', G H, and J) or in the presence of additional protease
t

inhibitors (lanes A-D, I, and K) or from muscle homogenates to which
previously purified liver-derived insulin receptors were added (lanes F
and F t

,

see "Experimental Procedures").

In experiments shown in lanes

A-G, WGA-purified receptors were incubated with Al4 l25I-insulin
without or with (lanes A and B) 50 ng/ml unlabeled insulin at 4 0 C for

16 hr.

Disuccinimidyl suberate (2 roM) was added for an additional 15

min when 4 X concentrated Laemmli's sample buffer was added.
and G illustrate cross-linked a

Lanes C

subunits derived from muscle, and

lanes D and E from liver; lanes F and F' illustrate the mixed
population from muscle and liver.

Electrophoresis was performed under

reducing conditions on a 6.5% resolving gel.

Lanes A-D and E-G are

derived from separate experiments; the two autoradiograms were aligned
according to the molecular weight markers.

In experiments shown in

lanes H-K, YGA eluates from muscle (lanes H and I) or liver (lanes J
and K) were incubated with insulin-agarose (29) for 16 h at 4°C,
phosphorylated and electrophoresed as described under "Experimental
Procedures. II
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Figure 2.

A:

Specificity of cross-linking 125I-Insulin to muscle and

liver receptors. Equal insulin binding activities of muscle- and
liver- dervied wheat germ eluates were incubated with l25I-insulin and
increasing concentrations of unlabeled insulin or IGF-l prior to crosslinking with DSS as described in Fig. 1.

Proteins were separated by

SDS-PAGE and the amount of 125I -insulin cross-linked was quantitated by
counting the excised labeled bands in a gamma counter.
the mean of duplicate determinations.

B:

Each point is

Equilibrium binding of A14

125 I -insulin to WGA eluates from muscle and liver.

WGA eluates from

muscle (50 ul) and liver (25 ul) were incubated as described (30) with

A14 125I-insulin and increasing concentrations of unlabeled insulin.
Receptor-bound l25I-insulin was precipitated wtih polyethylene glycol
(30).

Nonspecific binding was determined as that occurring in the

presence of 10 ug/ml unlabeled insulin, and subtracted from total
binding.

The data represent the mean of seven separate receptor

preparations from muscle and liver.
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CHAPTER V
SKELETAL MUSCLE INSULIN RECEPTOR TYROSINE KINASE:
EFFECTS OF SUBSTRATE INHIBITION AND DIABETES
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INTRODUCTION
The first known event after insulin binding is activation of the
intrinsic tyrosine kinase of the insulin receptor.

This activation

appears to be a prerequisite for most if not all of insulin's actions
and has been extensively characterized in vitro and to a lesser extent
in vivo (26,129,225).

Defects in kinase activity are observed in

adipose tissue (78,251) skeletal muscle (6) and liver (34) of patients
with non-insulin dependent diabetes (NIDDM) and experimental rat models
of insulin-dependent diabetes mellitus (IDDM).

These defects appear to

be aquired as they can be corrected by normalization of insulin levels
in insulinopenic rats (30,123) or by weight control in patients with
NIDDM (80).
We recently observed that diabetes induced decreases in liver
insulin receptor

tyrosi~e

kinase activity were more pronounced under

conditions where the receptor kinase was inhibited by the substrate
H2b. whereas near normal maximal intrinsic exogenous kinase activity
was observed under noninhibitory conditions.

In addition no

diabetes-related impairment of the hepatic insulin receptor
tyrosine-kinase were observed when using the substrate poly glu-tyr
(4:1).

In the present study we examined the effects of various

concentrations of histone H2b and poly glu-tyr (4:1) on exogenous
kinase activity of the insulin receptor from skeletal muscle of control
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and diabetic rats.

We also examined the effects of the severity of

diabetes on skeletal muscle insulin receptor kinase activity in vitro.

MATERIALS AND METHODS
Materials:

All materials and sources were as described previously

in chapter 3 of this dissertation.
Animals:

Male Wistar BR rats (Charles River laboratories, Wilming-

ton, MA) weighing 100-200 g were allowed access to standard rodent chow
and water ad libitum.

Diabetes was induced with a single intravenous

dose of streptozotocin in citrate buffer, pH 4.5, to overnight fasted
rats.

In most studies, rats were given a dose of 85-120 mg/kg strepto-

zotocin and studied 2-3 weeks following induction of diabetes.

In one

experiment, differences in the severity of diabetes were studied after
the injection of either 50 mg/kg or 85 mgfkg streptozotocin and the
rats were killed one week later.

Heparinized blood samples were

obtained by cardiac puncture of anesthetized rats prior to excision of
hindlimb muscles.
Plasma metabolites:

Glucose was measured by the glucose oxidase

method using a Beckman glucose analyzer II.

Insulin was measured by a

double antibody radioimmunoassay as described previously (83).
-hydroxybutyrate was measured by fluorometric assay as described
previously (294).
Insulin receptor purification:

Muscles (-2 g) from anesthetized

control or diabetic rats were frozen in liquid nitrogen and insulin
receptors were solubilized and partially purified by WGA affinity
chromatography as described in chapter 3 of this dissertation.
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Insulin binding:

Equilibrium insulin binding was performed as

described previously in chapters 2 and 3 of this dissertation.
Exogenous substrate kinase assays:

In vitro exogenous kinase

assays towards histone H2b and poly gluMtyr (4:1) with equal insulin
binding activity (-25 fmoles) of control and diabetic insulin receptors
were carried out as described previously

(chapter 3).

Separation of

proteins by SDS-PAGE was carried out as described previously (chapters

2 and 3).

Kinase assays involving multiple substrate concentrations

were performed on one pair of diabetic- and control- derived WGA
eluates at a time.

Data obtained using receptors prepared from muscles

of control and diabetic rats are reported as the percent of maximal
kinase activity obtained from control receptors in each experiment to
minimize variability due to differences in specific activities of ATP
between experiments.
Preparation. isolation and characterization of insulin receptor
dimers and tetramers was carried out as described previously in chapter
3 of this dissertation.

Statistical analysis:

Statistical analyses were performed by the

students t-test or the paired students t-test when control- and
diabetic- derived receptor preparations were assayed in pairs.
Analysis 'of variance were performed on data from experiments with
insulin dose-responses and differing severity of diabetes.
RESULTS
Inhibition of exogenous kinase activity by H2b:

Figure 1 shows

the exogenous kinase activity towards H2b of insulin receptors solubil·
ized from control and diabetic hindlimb muscle when histone was added
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prior to receptor autophosphorylation.

As previously reported with

liver (chapter 3 of this dissertation) increasing the concentration of
H2b to .008 mg/ml and above under these conditions resulted in an
obvious reduction in exogenous kinase activity towards this substrate.
However. at the lowest concentration of H2b tested (.008 mg/ml) there
was no significant difference in the kinase activity between receptors
derived from control and diabetic muscle, while a significant decrease
was observed in diabetic liver at this concentration compared to
control liver (chapter 3, fig la).

At higher concentrations of H2b

(.04 - 1 mg/ml) the insulin stimulated kinase activity of receptors
from diabetic muscles was significantly lower than that of receptors
from control muscle when analyzed by paired t-test.

Basal kinase

activity was also inhibited by H2b and like liver, this inhibition was
observed at higher levels of H2b than the insulin stimulated reaction.
Significant differences between basal kinase activity of control and
diabetic-derived insulin receptors were also found only at

su~strate

concentrations which resulted in inhibition of exogenous kinase
activity (0.2 - 1 mg/ml).

These results indicate that, similarly to

liver, the diabetic derived muscle receptor kinase appears to be
inhibited more than that from controls in the presence of H2b.
However, receptors derived from diabetic muscle are inhibited to a
lesser extent by this substrate than receptors from diabetic liver when
compared to their respective controls under similar conditions (compare fig 1, chapter 3 to fig 1 chapter 5).
Inhibition of autophosphorylation by H2b:

The amount of phosphate

incorporated into the S subunit of the receptor was quantified in the
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reactions described in figure 1 and are shown in figure 2.

We observed

no significant difference in basal or insulin stimulated autophosphorylation of insulin receptors derived from control and diabetic muscle at
any concentration of H2b.

The Kiapp (determined by the concentration

of histone required for half maximal inhibition) for autophosphorylation was similar between the two groups (-0.4 mg/ml H2b).

This

value was similar to that observed with control and diabetic liver
(chapter 3, fig 3).
Tyrosine kinase activity towards H2b after activation with insulin
and ATP:

Addition of increasing concentrations of H2b to reactions

after insulin receptors were pre incubated with ATP at 4°C resulted in a
dose-dependent increase in exogenous kinase activity towards this
substrate with WGA eluates isolated from muscles of control and
diabetic rats (fig 3).

No significant difference in exogenous kinase

activity was observed between control and diabetic-derived insulin
receptors at any concentration of H2b tested.

The Kmapp and Vmaxapp

for H2b were not significantly different between receptors isolated
from control and diabetic muscle (0.0505 + 0.0111 vs 0.0407 + 0.0056
mg/ml and 30.4 + 10.04 vs 27.1 ± 8.8 fmoles Pi/fmole receptor/4 min,
respectively) under these conditions when analyzed by fitting the data
by nonlinear regression to the Michaelis-Menten equation.

Under these

conditions, no apparent inhibition of autophosphorylation occurred and
no significant differences between control and diabetic autophosphorylation were detected (fig 4).
Kinase activity towards poly glu-tyr (4:1):

In previous experi-

ments with liver, no differences in the exogenous kinase activity
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towards the synthetic substrate poly glu-tyr (4:1) were found between
control and diabetic-derived receptors (chapter 3, fig 8).

We there-

fore measured exogenous kinase activity of WGA eluates derived from
control and diabetic muscle towards poly glu-tyr (4:1) without or after
incubation with several insulin concentrations.

Insulin resulted in a

dose-dependent activation of both control and diabetic insulin receptor
kinase activity towards this substrate (fig 5).

While the kinase

activity of diabetic-derived receptors assayed without or with lO-lOM
insulin was significantly decreased compared to controls when analyzed
by t-test, when data were analyzed by analysis of variance (Peritz'
F-test), no significant difference was found between control and
diabetic-derived receptors in the absence or presence of any insulin
concentration tested.
Kinetics of insulin receptor kinase activity towards poly glu-tyr

(4:1):

To assess whether effects of diabetes similar to those seen

with inhibitory levels 6f histone H2b are also expressed towards
poly-glu-tyr (4:1), increasing concentrations of poly glu-tyr (4:1)
were incubated with

rec~ptors

derived from control and diabetic muscle

after incubation without or with lO-7M insulin.

Fig 6 shows the

resulting dose-response curves of exogenous kinase activity after
exposure to ATP.

A biphasic dose-response curve was observed with both

diabetic and control receptors, with no significant difference in the
kinase activity at any concentration of poly glu-tyr.

These data

indicate that as observed with liver, the diabetes associated impairment of insulin receptor kinase activity appears to be selective for
substrates in skeletal muscle.
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Severity of diabetes:

Insulin receptor tyrosine kinase activity

towards H2b from skeletal muscle of diabetic rats was highly variable,
(-20-100% of controls in individual pairs) when an inhibitory concentration of H2b (0.4 mg/m1) was added prior to receptor activation.
Since the metabolic response of rats to streptozotocin is often
variable, we hypothesized that the variability in exogenous kinase
activity may be due to variability in the degree of diabetes.

There-

fore, exogenous tyrosine kinase activity towards H2b (0.4 mgjml) was
assessed in muscle derived WGA eluates from control rats or rats given
a moderate (50 mgjkg STZ) or high (85 mgjkg STZ) dose of streptozotocin
in an attempt to produce a moderate or severe diabetic state (fig 7).
Rats with moderate diabetes grew at a rate of -5 gjday while those with
severe diabetes grew an average of -2 gjday compared to a weight gain
of -7 g/day for controls.

Rats in the moderate group were considered

to be diabetic by elevated plasma glucose levels (448 ± 19 mg/dl) which
were similar to the severely diabetic rats (497 + 61 mgjdl, n-3 per
group).

Plasma glucose levels in both diabetic groups were not

significantly different from each other but were significantly
elevated compared to controls (132

±

2.3 mgjdl, p <.01).

The exogenous

kinase activity of receptors from muscle of severely diabetic rats
assayed at inhibiting levels of H2b was decreased

by -50% or 70% for"

basal and insulin stimulated kinase activity, respectively, (p <.05)
compared to concurrently assayed controls.

The kinase activity of the

moderately diabetic group was not significantly different from controls in the same experiment.

These results suggest that defects in

insulin receptor kinase activity in muscle are only expressed in
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severely diabetic rats.
Circulatins metabolites:

Circulating glucose and

B -hydroxy-

butyrate levels in the plasma of control and severely diabetic rats (85
- 120 mg/kg streptozotocin i.v.) were measured to assess whether the
concentration of either of these metabolites correlated with the
decreases in muscle insulin receptor kinase activity.
concentrations of glucose and

The mean plasma

B -hydroxybutyrate were markedly

increased in severely diabetic rats (Table 1).

Insulin levels were

significantly decreased, in the diabetic group, often to undetectable
levels, therefore attempts were not made to correlate insulin levels
with kinase activity.

However, since growth is related to circulating

insulin levels, attempts were made to correlate the percent change from
the initial body weight at the time of sacrifice with exogenous kinase
activity.

No significant correlation was found between decreases in

exogenous kinase activity towards H2b (expressed as % of control) and
plasma glucose,

8-hydroxybutyrate or % change in body weight (not

shown).
Detection of insulin receptor tetramers and dimers:

Equilibrium

125I-insulin binding carried out in pH 7.6, high salt buffer with
fractions eluting from gel filtration columns is shown in figure 8.
Binding from native (not treated with DTT) receptors isolated from
control and diabetic derived muscles eluted in fractions corresponding
to a M.W. of -400 kD, whereas binding from DTT-treated receptors eluted
at a M.W. of -200 kD.

No binding was detected in fractions eluting at

a M.W. of N200 kD from native control or diabetic muscle preparations,
with insulin binding activity assayed in either pH 7.6, high salt (fig
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8) or pH 7.0, low salt buffer (data not shown; the low-salt pH 7.0
buffer is optimal for insulin binding by dimers but not for tetramers).
These data were confirmed by specific crosslinking of 125I-insulin to
the insulin receptor species followed by nonreducing SDS-PAGE (fig 9).
Dimers were identified in fractions eluting at a M.W. of -200 kD from
gel filtration columns after DTT treatment of control receptors (lanes
A and B) and were absent in fractions eluting at a M.W. of -400.

Dimers were not detected after gel filtration of native control (lanes

E and G) and diabetic receptor preparations (lanes J and L).

In the

native preparations intact tetramers were identified in fractions
which eluted from gel filtration columns at a M.W. of -400 kD from both
control (lane E) and diabetic (lane J) preparations.
DISCUSSION
Tissue-specific differences in the structure and function of the
insulin receptor exist (28,35,107,120,220)

B

We reported that the a and

subunits of the liver insulin receptor migrate slower on SDS-PAGE

than the corresponding subunits from muscle (28).

The differences were

attributed in part to increased sialic acid content of the
of liver.

a

subunits

Further studies in our laboratory and others have shown

functional differences in insulin receptor kinase activity between
insulin receptors derived from human placenta and liver (194); and
between liver and muscle from rats (32) and humans (35).

Insulin

receptors derived from rat skeletal muscle possessed -2 fold greater
autophosphorylation and exogenous kinase activity than receptors
derived from rat liver (32), and rat liver-deriyed insulin receptors
were -3 times more active than receptors from human placenta per
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insulin binding site (194).
Insulinopenic diabetes results in altered structure and function
of the insulin receptor.

The

B subunit of the insulin receptor derived

from diabetic skeletal muscle was found to migrate with a higher
M.W. app than controls; and this was attributed in part to increased
sia1ylation of the B subunit in a subpopulation of receptors (30).
Skeletal muscle insulin receptors from diabetic animals also possessed
decreased insulin stimulated autophosphory1ation and exogenous kinase
activity towards the substrates histone H2b and angiotensin II (30).
In this study, we found differences in the effects of diabetes on the
rat skeletal muscle insulin receptor kinase compared to what we and
others (195) observed with liver derived receptors.
Like the liver insulin receptor, the skeletal muscle insulin
receptor kinase is inhibited by high levels of the substrate histone
H2b. although the concentrations of H2b required for inhibition are
higher in muscle than in liver.

Differences in exogenous kinase

activity towards H2b between receptors isolated from control and
diabetic muscle were detectable, but the concentrations of H2b required
were 10 - 20 fold higher with muscle derived receptors than with those
from liver.

When inhibition was apparently overcome by autophos-

phorylation of the receptor prior to substrate addition, no difference
in exogenous kinase activity was observed between diabetic- and
control- derived receptors at any histone concentration.

Under these

conditions, no differences in the Kmapp or Vmaxapp for H2b were
detected between the two groups.

In contrast, the maximal velocity

towards H2b of diabetic-derived liver receptors was only -75% of
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controls when assayed similarly (chapter 3, fig 6).

While with both

muscle- and liver-derived receptors from diabetic rats the major
functional defect appear to be enhanced substrate inhibition, an
impairment of the fully phosphorylated enzyme was only detectable in
liver derived receptors.

We previously observed significant diabetes

associated impairment of kinase activity towards H2b after in vivo
activation of the control and diabetic hindlimb muscle insulin receptor
tyrosine kinase (chapter 2, fig 9).

Thus, while the intrinsic fully

phosphorylated phosphotransferase activity of the solubilized skeletal
muscle insulin receptor kinase is unaltered in diabetic rats, in vivo
conditions preclude complete activation of the receptor kinase per
insulin binding site.

The mechanism in vivo may be similar to that

observed in vitro i.e. inhibition of activation by endogenous receptor
substrates and may reflect structural alterations in the diabetic
receptor or its microenvironment that render kinase activation more
susceptible to

substrat~

inhibition in vivo.

A previous study from our laboratory reported a significant
decrease in exogenous k,inase activity towards H2b in muscle derived
insulin receptors from diabetic rats vs controls after in vitro
activation (30).

In that study solubilized receptors were adsorbed to

insulin agarose and incubated with maximally activating levels of ATP
prior to the histone-kinase assay.

Differences in results between the

two studies are probably not due to the use of immobilized receptors
in the former as no significant differences in kinase activity towards
H2b were observed when control- and diabetic- derived receptors were
activated similarly on insulin agarose in the present study (data not
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shown).

The reasons for the discrepancies are unclear, but may involve

differences in the severity and/or duration of diabetes.

In the

present study (Fig 3) rats were killed between 2·3 weeks after induction of diabetes while in the previous one they were killed within 5·7
days.

Very severely compromised rats (i.e. with diabetic ketoaci-

dosis) usually do not survive past one week of experimental diabetes
without insulin replacement and therefore would not be included in the
population of rats shown in Fig 3.
As with liver, we did not observe differences in the exogenous
kinase activity towards the synthetic substrate poly glu-tyr (4:1).
Bak et a1. (9) also did not observe differences in exogenous kinase
activity towards this substrate using skeletal muscle insulin receptors
derived from normal volunteers and patients with insulin-dependent
diabetes mellitus with documented insulin resistance.

Substrate

selective effects of insulinopenic diabetes on insulin receptor kinase
activity are therefore expressed in both muscle and liver.
As in a previous report from our laboratory (32), insulin
receptors derived from muscle possessed -2 fold greater autophosphory·
lation and exogenous kinase activity towards the substrate poly glu-tyr
(4:1) and histone H2b compared to liver.

Differences in exogenous

kinase activity between tissues were due to differences in the Vmaxapp
towards these substrates, consistent with previous results indicating a
population of receptors in liver which are kinase inactive (32).

We

did not detect the presence of insulin receptor dimers in control or
diabetic muscle t or liver indicating that differences in kinase
activities between control muscle and liver or between diabetic and
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control muscle are intrinsic to the native tetramer.
Numerous reports exist of the effects of noninsulin-dependent
diabetes mellitus (NIDDM) on insulin receptor tyrosine kinase activity
in several tissues in humans (6,34,78,251).

In liver (34), adipose

tissue (78,251) and skeletal muscle (6,189) impaired exogenous kinase
activity towards poly glu-tyr (4:1) have been observed in patients with
NIDDM.

Our results with muscle in the rat and those of Bak et ala (9)

in man suggest that the mechanisms responsible for altered exogenous
kinase activity may be different in IDDM (type 1) and .NIDDM (type 2)
diabetes.

Furthermore, a severe metabolic disorder is required before

decreased exogenous kinase activity is observed in vitro in muscle of
rats with STZ-diabetes; whereas in NIDDM, kinase defects are observed
with moderate metabolic alterations.

Okamoto et ala (195) observed

decreases in exogenous kinase activity towards H2b of receptors derived
from liver of rats with moderately severe STZ-diabetes.

Those results

and results from this study suggest differences in the sensitivity of
muscle and liver insulin receptors to insulinopenic diabetes.
Similarly, others have observed markedly reduced kinase activities of
receptors derived from liver of rats rendered insulin resistant by high
fat diets (22) and fasting (10) with no significant effect on the
insulin receptor kinase derived from skeletal muscle of the same rats.
Thus, the muscle insulin receptor may be spared when metabolic
alterations are relatively mild.

Alterations in metabolites which

occur in IDDM include increased circulating glucose, free fatty acids,
glucocorticoids, catecholamines and ketone bodies (155,160,203,267).
We and others previously showed that hypercortisolemia in rats does not
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affect exogenous kinase activity of the adipocyte (272) or skeletal
muscle (18) insulin receptor.

Others have shown that catecholamines

decrease exogenous kinase activity and insulin binding

~ffinity

(188).

We did not find a correlation between plasma glucose,

a-hydroxy-

butyrate, or percent decrease in body weight and reduction of exogenous
kinase activity.

However, plasma samples used for these studies came

from rats with relatively severe diabetes (i.e. average weight gain for
all diabetic rats was essentially zero).

It is possible that if a

wider range of diabetic animals was studied (as in fig 7), correlations
may exist between these parameters and exogenous tyrosine kinase
activity.
In humans with IDDM, insulin resistance is related to the degree
of control of diabetes (58,173).

While insulin resistance is not the

primary defect in IDDM (160,203) it is a prominent feature of diabetic
ketoacidosis (155,203).

Skeletal muscle, due to its mass is

responsible for most of the insulin stimulated glucose transport and
utilization of the organism (59,141); and for the same reason, when
defective, is also the major site of insulin-resistant glucose
transport and utilization (55). -Defects in muscle insulin receptor
tyrosine kinase activity were observed only in severely "diabetic rats
suggesting that impaired skeletal muscle insulin receptor signalling
may contribute to the severe insulin resistance observed in diabetic
ketoacidosis.

154
Tyrosine kinase activity towards H2b, plasma glucose and
plasma ~-hydroxybutyrate levels fro. control and diabetic
rats.

Table 1.

H2b Kinase Activity
(% of control)

Glucose
(mg/d1)

100 + 3.0 (25)

144 ± 4.3 (14)

240 ± 12.7 (33)

593 + 2.95 (23)*

2057 + 220 (44)*

Control
Diabetic

71 ± 3.1 (46)*

Results are presented as the mean ± S.E.
Values in parentheses ~ number of rats per group
*p < 0.01 compared to controls

ft-hydroxybutyrate
(uK)
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Figure 1.

Inhibition of exogenous tyrosine kinase activity by H2b.

Equal insulin binding activities of WGA eluates derived from control
and diabetic muscle were incubated without or with 10- 7 M insulin for
16 hr in buffer containing 50 mM Hepes, 0.1% Triton X-100, 5 mM MnCI2'
0.55% BSA, pH 7.4 at 4 o C, followed by increasing concentrations of H2b
(0.008 - 1 mg/m1) for 10 min at 25 0 C.

Phosphorylation was initiated by

the addition of 25 tiM y [32 p ]ATP and r~actions were stopped after 4 min
at 25°C by the addition of 4X Laemm1i's sample buffer.

Following SDS-

PAGE and treatment of gels with 1 N NaOH for 1 hr at 55°C, H2b and
subunit bands were localized by autoradiography, excised and 32p
counted by scintillation spectrophotometry.
plus insulin.

- - minus insulin, + -

Data represents the mean ± S.E. of 4-7 receptor

preparations. *p < 0.05 by paired t-test
pairs, plus insulin).

(n~4

pairs, minus insulin; n-7
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Figure 2.

Inhibition of autophosphory1ation by H2b.

Quantification of

insulin receptor autophosphorylation in reactions described in figure
1 is shown.
preparations.

Data represent the mean + S.E. of 4-5 receptor
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Figure 3.

H2b kinase activity of insulin receptors after

prephosphorylation at 4°C.

Equal insulin binding activities of WGA

eluates derived from control and diabetic muscle were incubated without
or with 10- 7 M insulin in buffer as described in the legend to figure
1.

Phosphorylation was then initiated by the addition of 25 uK Y

[32 p ]ATP.

After 30 min at 4°C, histone H2b (0.04 -1.0 mgjml) was added

and reactions were stopped after an additional 20 min at 4 0 C by the
addition of 4X Laemmlits sample buffer.

Proteins were then separated

by SDS-PAGE and the gels processed as described in the legend to figure
1.

Data represents the mean + S.E. of 5-6 receptor preparations.
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Figure 4.

Autophosphorylation of control and diabetic derived muscle

insulin receptors.

Quantification of 32p incorporated into the

subunits of the insulin receptors in reactions described in the legend
to figure 3 is shown.
preparations.

Data represent the mean + S.E. of 5-6 receptor
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Figure 6.

Kinetics of insulin receptor kinase activity towards poly

glu-tyr (4:1).

Equal insulin binding activities of WGA eluates derived

from control and diabetic muscle were incubated without or with 10- 7 M
insulin in buffer as described in the legend to figure 5.
(4:1) (0.05 - 10 mg/m1) was then added for 10 min.

Poly glu-tyr

Phosphorylation was

initiated by the addition of 25 uM y[32 p ]ATP and reactions were
stopped after 4 min at 2S o C as described in Materials and Methods.
- - minus insulin, +

=

plus insulin.

S.E. of 3 receptor preparations.

Each point represents the mean ±
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Figure 7.

Severity of diabetes.

(0.4 mg/ml) was

as~ayed

Tyrosine kinase activity towards H2b

as described in legend to figure 1 with WGA

eluates derived from muscle of control rats and rats rendered diabetic
with a moderate (50 mg/kg) or high (85 mg/kg) dose of streptozotocin.
Data represent the mean + S.E. of 3 receptor preparations.

*

p < 0.05 by analysis of variance (Peritz' F-test).
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Figure 8.

Equilibrium 12SI-Insulin binding to isolated insulin

receptor dimers and tetramers.

Native and DTT-treated WGA eluates

derived from control and diabetic liver were subjected to gel
filtration as described in Materials and Methods.

Fractions were

incubated with 125I-Insulin (10- 11 M) without or with 10. 6 M unlabeled
insulin in binding buffer (pH 7.6, 150 mM NaCl) as described in
Materials and Methods.

Receptor-bound insulin was precipitated with

polyethylene glycol and samples were counted as described in.Materials
and Methods.

The single and double arrows denote the elution of

Ferritin (440 K) and Myosin (205 K) molecular weight standards,
respectively.
determinations.

Data shown is a representative of 3 separate
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Figure 9.

Identification of dimers and tetramers by SDS-PAGE after

crosslinking with l25r-rnsulin.

Native and DTT-treated WGA eluates

derived from control and diabetic muscle were subjected to gel
filtration as described in Materials and Methods.
a M.W. of

~200

Fractions eluting at

kD (lanes A,B,C,D,G,H,K and L) or -400 kD (lanes E,F,I

and J) were then incubated with 125I-Insulin, without (lanes
A,B,E,G,J, and L) or with (lanes C,D,F,H,I, and K) 10- 6 M unlabelled
insulin, and proteins were separated by non-reducing SDS-PAGE after
addition of 2 roM NEM as described in Materials and Methods.

Fractions

from native control- and diabetic-derived WGA eluates are shown in
lanes E-H and I-L, respectively.

Fractions from DTT-treated control

WGA eluates are shown in lanes A-D.

The single arrow indicates th

migration of the a282 tetramer and the double arrows indicate the
migration of the as dimer.
separate experiments.

This is a representative one of three
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CHAPTER VI

SUMMARY AND CONCLUDING REMARKS
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Studies in the preceding chapters concerned the role of the
insulin receptor tyrosine kinase in insulin resistance with particular
emphasis on the insulin resistance which occurs in response to insulinopenia.

Soon after the initial discovery of the tyrosine kinase

activity intrinsic to the insulin receptor, a number of laboratories
demonstrated that in some insulin resistant states the insulin receptor
possessed decreased tyrosine kinase activity.

Those studies were the

among the first to suggest a role of the insulin receptor tyrosine
kinase in insulin action.

The studies in this dissertation were

initiated during that time, when it was still controversial whether the
receptor kinase was essential to the signalling process.

Studies

concerning the in vivo activation of the insulin receptor in chapter II
were among the first to show insulin dose-dependent activation of the
insulin receptor in skeletal muscle in the intact rat.

These studies

were ongoing when cloning and mutation of the insulin receptor gene
provided convincing evidence that activation of the insulin receptor
kinase was necessary for signal transmission by the receptor
(40,68,71).
Insulinopenic diabetes is accompanied by increases in several
hormonal insulin antagonists including glucocorticoids (267).

Some of

the studies presented in chapter II were carried out to establish
whether glucocorticoids decrease insulin receptor tyrosine kinase
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activity.

These studies indicated that glucocorticoids antagonize

insulin's actions at steps distal to the insulin receptor kinase.
Similar studies in other laboratories subsequently showed that
glucocorticoids do not impair the rat adipocyte (272) or liver (132)
insulin receptor kinase.

These three studies indicate that in the

three major physiologic target tissues of insulin, the insulin
resistance of glucocorticoid excess is a true post-receptor defect.
However, it appears that under post-absorptive conditions, the
instrinsic tyrosine kinase activity of the rat liver insulin receptor
is reduced in the presence of glucocorticoids indicating a permissive
role of glucocorticoids in altering the insulin receptor kinase in some
nutritional states (132).

Similarly, glucocorticoids may playa role

with other hormones resulting in reduced kinase activity of the insulin
receptor in diabetes.

Measurements of insulin receptor tyrosine kinase

activity from adrenalectomized diabetic rats are warranted in the
future to address this issue.
All of the studies prior to initiation of those in this dissertation which addressed the effects of insulinopenic diabetes on insulin
receptor kinase activity were performed with detergent solubilized,
partially purified receptors activated by insulin in vitro
(30,85,123,195).

It remained important to establish whether activation

of the insulin receptor kinase in vivo was impaired in the
streptozotocin rat model before further attempts were made to
characterize the receptor defect.

Studies in chapter II utilized a

method developed previously in our laboratory to assess the in vivo
activation state of the receptor in an in vitro system.

These studies
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showed that activation of the skeletal muscle insulin receptor kinase
is markedly reduced in vivo by insu1inopenic diabetes.
Studies were undertaken to characterize defective insulin
receptor tyrosine kinase activity from diabetic muscle and liver
(chapters III and IV).

Defects in insulin receptor kinase activity

from diabetic liver and muscle were observed with histone H2b but not
poly glu-tyr (4:1).

Kinetic studies with histone H2b revealed that

while the intrinsic kinase activity (e.g. after maximal autophosphorylation) of the insulin receptor from diabetic rat liver (chapter III)
is slightly impaired, it appeared that a major reduction in exogenous
kinase activity towards this substrate was due to inhibition of
activation by H2b.

Similar results, e.g. decreased exogenous kinase

activity towards H2b due to inhibition by H2b were observed in receptors derived from diabetic compared to control muscle (chapter V),
although the kinase defect in receptors from diabetic muscle appeared
to be solely due to inhibition by H2b.

After maximal activation of the

insulin receptor in vitro, kinase activity of the diabetic skeletal
muscle insulin receptor was essentially the same as controls.

Compari-

son of the results obtained in vitro and in vivo with diabetic muscle
suggest that the environment in vivo must modulate diabetic skeletal
muscle insulin receptor kinase activity.

These modulators may inhibit

exogenous kinase activity by a similar mechanism as H2b.
Kinetics of H2b kinase activity from liver (chapter III)
suggested that the insulin receptor tetramer contains more than one
substrate binding site.

The simplest interpretation of the data was

that binding of substrate to one of the

subunits in the tetramer
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complex alters the kinetics of the other

subunit.

Substrates for the

receptor kinase may thus act as activators at low concentrations, and
as inhibitors at high concentrations.

This may be an important means

by which activity of the insulin receptor can be regulated depending on
availability of substrates and in addition the structure of available
substrates in the cell.

Since studies in this dissertation were

primarily concerned with comparison of the kinetics of control and
diabetic insulin receptors, further studies are necessary to test the
above hypothesis concerning substrate regulation of insulin receptor
kinase activity.
One of the recurring conclusions from all of the studies presented in this dissertation was the necessity of defining and characterizing the endogenous substrates for the insulin receptor.

Methodologi-

cal difficulties have obfuscated considerable effort by others in our
laboratory and elsewhere to elucidate relevant substrates until very
recently (45,214).
histones.

Histone H2b is a lysine-rich subfraction of mixed

Lysine rich peptides (po1ylysine, H2b and the carboxyl

terminus of the human C-ki-ras 2 gene product) are required as
cofactors for the in vitro insulin-stimulated phosphorylation of some
receptor substrates including calmodulin (90,130,231,235).

This

suggests that basic amino acids may be important for interaction of the
insulin receptor with other molecules.

The effects observed with H2b

in the studies presented in chapter III and V may be a model for the
interaction of the insulin receptor with other basic proteins.

It is

noteworthy that the c-ki-ras 2 gene product is a member of the highly
conserved family of G proteins (37,231)..

Recent studies which
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demonstrated the hydrolysis of an inositol-glycan mediator following
insulin stimulation of intact cells suggests that insulin activates an
inositol-specific phospholipase C in the plasma membrane of cells.

In

well defined systems, phospholipase C activation occurs after
interaction of specific receptors with G proteins in the plasma
membrane (43,241).

Although it is unclear at this time whether this

function is mediated by a G protein, studies have shown evidence for
interaction of the insulin receptor with G proteins (153,190,230).
Furthermore, intracellular microinjection of

anti-p2~

ras antibody

inhibits insulin stimulated maturation of Xenopus oocytes (150).

Of

particular relevance to the present -studies (chapters III and V) is
that P21 ras inhibits autophosphorylation of purified insulin receptors
(191).

Therefore, potentially, an alteration in the receptor by

diabetes which alters its interaction with an insulin responsive G
protein could alter insulin's effects.

Conversely, antagonism of'

insulin's actions by hormones known to activate specific G proteins
(hormones which increase cAMP or activate protein kinase C) could arise
by an interaction of these G proteins with insulin receptors to inhibit
insulin's actions.
Metabolic effects of insulin are often tissue specific.

The

classic response to insulin, i.e. glucose transport, is insulinindependent in liver, whereas muscle and adipose tissue are largely
dependent on insulin to stimulate glucose transport into cells.

The

evolutionary development of protein isotypes confers tissue-specificity
to enzymes such as lactate dehydrogenase.

Studies in chapter IV

showed tissue-specific differences in the structure of muscle and
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liver-derived insulin receptors.

Further studies by others in our

laboratory showed that the muscle-derived insulin receptor possesses
approximately 2-fold greater intrinsic
ous kinase activity than liver (32).

autophosphoryla~ion

and exogen-

Whether the differences in

structure and function result from preferential expression of different

mRNA isoforms needs to be established.
Comparison of the results in chapters III and V highlighted
apparent tissue-specific differences in the response of the insulin
receptor to insulinopenic diabetes.

Variability in the tyrosine

kinase activity of insulin receptors derived from diabetic muscle was
partly explained by variability in the severity of diabetes.

These

studies and studies by others of the response of the skeletal muscle
and liver insulin receptor to fasting and high fat feeding suggest that
the insulin receptor from muscle is "spared" under mildly altered
metabolic conditions while the insulin receptor from liver is not.
In summary, insulin receptor tyrosine kinase activity is
modulated in some but not all insulin resistant states.

Regulation of

insulin receptor tyrosine kinase activity in type 1 diabetes appears
to be different from that in type II diabetes.

Regulation of insulin

receptor tyrosine kinase activity in type 1 diabetes may be tissue
specific.

Furthermore the availability and structure of substrates may

modulate regulation of insulin receptor tyrosine kinase activity in
vivo in cells from insulinopenic organisms.
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